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The growing deficit in suitable tissues for patients awaiting organ transplants 
demonstrates the clinical need for engineered tissues as alternative graft sources. In skeletal 
muscle, volumetric muscle loss is any injury exceeding the normal muscle repair mechanism and 
resulting in permanent functional impairment. Because available treatments seeking to fill the 
damaged site with healthy graft tissue are limited by a lack of suitable graft sources, tissue 
engineering of skeletal muscle has been identified as a promising alternative. To date, however, 
engineered muscles across the field have generated a fraction of the specific force present in 
native muscle, and this limitation may present a barrier to clinical applicability. This study 
addressed this force disparity by promoting in vitro muscle development through the following 
specific aims: 1) Improving myogenic purity of isolated muscle stem cells with microfluidic inertial 
separation, 2) Increasing myogenic differentiation in developing cells and engineered muscles 
with dexamethasone steroid supplementation, and 3) Evaluating engineered tissue structure and 
function in a non-invasive, label-free manner using multiphoton microscopy. All three 
experiments demonstrated significant improvements in engineered skeletal muscle force 
production as compared to previous fabrication methods. Especially as tissue-engineered 
skeletal muscle moves towards translation as a strategy for repairing volumetric muscle loss, 
consistently improving in vitro force production of engineered skeletal muscle using methods 
established in this dissertation is essential for advancing both our tissue engineering model and 








Skeletal Muscle Physiology 
Skeletal muscle is a soft tissue composing approximately 40% of the total mass of the 
human body1. Skeletal muscle creates voluntary motion of the human body, acting in response 
to electrical signals from the nervous system to generate force that is transmitted through 
tendons to the skeleton. Generation of contractile force is the primary function of skeletal 
muscle2, and this functional behavior is closely related to its complex structure.  
On the cellular level, muscle fibers or myofibers are the motors responsible for force 
generation. During development, myofibers are formed by fusion of mononucleated myoblasts 
into multinucleated myotubes (See Figure 1)2. Cylindrical in shape, myofibers can extend the full 
length of a given muscle. Each myofiber is composed of myofibrils arranged in parallel along its 
length. Division of myofibrils into a repeating pattern of sarcomeres gives skeletal muscle a 
striated appearance under high magnification and ultimately enables contractile behavior of the 
entire skeletal muscle system. Sarcomeres contain overlapping bands of the proteins, actin and 
myosin, that slide over each other during a contraction to generate force2. Overall force 
production by a given muscle fiber depends on the number of sarcomeres acting in parallel, a 
number that is directly related to the overall muscle cross-sectional area due to the uniform 
sarcomeric architecture. Figure 1 shows how sarcomeres in series form muscle fibers and how 
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muscle fibers are bundled into fascicles. In turn, several fascicles are bundled together to form 
an entire muscle, surrounded by an outer sheath termed the epimysium. Thus, it is clear how the 
structure of skeletal muscle is organized to maximize function, with each contractile unit, or 
sarcomere, repeated in a modular manner in progressively larger tissue subcomponents from 
myofibrils to myofibers to fascicles to whole muscles. 
       
 
Figure 1. Hierarchical structural organization of 
skeletal muscle. Sarcomeres, formed by 
overlapping bands of myosin and actin, act as 
molecular motors to generate contractile force. 
These basic structural units are repeated in 
successively larger subcomponents, from myofibrils 
to muscle fibers to fiber bundles to the whole 
muscle. Adapted from Widmaier et al.2 
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On a tissue level, skeletal muscle is organized to provide access for the required stimuli 
and nutrients and the necessary matrix to transmit generated force. To support myofiber 
contraction, connective tissue, blood vessels, and nerves are thus present in the complex skeletal 
muscle architecture1,2. Nerve cells, specifically motor neurons, provide nervous control of muscle 
cells. As a highly metabolic tissue, skeletal muscle also requires vascularization via blood vessels 
and capillaries. As a result, each myofiber has a source of blood and nervous control in the 
endomysium, a layer of surrounding connective tissue. One of the key functions of connective 
tissue in skeletal muscle, especially the endomysium, is maintaining the complex architecture 
needed to provide both metabolites and nerve stimuli to each myofiber.  
As one would expect based on the highly-organized structure of skeletal muscle, 
disruption due to trauma or disease severely affects the ability to produce force. The human body 
naturally repairs basic skeletal muscle injuries such as strains or tears, but traumatic damage 
often requires medical intervention3. The most prevalent such injury is volumetric muscle loss 
(VML), trauma overwhelming the normal muscle repair mechanism and resulting in permanent 
functional impairment and physical deformity4. Currently, clinical VML treatments have 
limitations including donor site morbidity and graft tissue scarcity3. Therefore, tissue engineers 
seek to fabricate skeletal muscle as an alternative graft tissue. Skeletal muscle tissue engineering 
approaches typically utilize muscle satellite cells to mature into a functional muscle construct. 
One of the primary challenges for tissue engineers, however, is obtaining the appropriate cellular 
component necessary for engineering skeletal muscle. The following section presents several 
techniques for addressing this issue, paying particular attention to: 1) cell isolation methods, 2) 




Skeletal Muscle Stem Cells 
The text and figures in this sub-chapter were originally published with the following 
citation: Syverud BC, Lee JD, VanDusen KW, and Larkin LM. “Isolation and purification of satellite 
cells for skeletal muscle tissue engineering.” J Regen Med 3(2): 117 (2014)5.  Excerpts from this 
article have been included with permission from the publisher, SciTechnol. 
Due to its tissue-specific regenerative potential, the satellite cell has been identified as 
the ideal progenitor cell for skeletal muscle tissue engineering6,7. In the early 1960’s Mauro 
originally described the resident skeletal muscle stem cell, the satellite cell, by its cellular location 
beneath the basal lamina of a skeletal muscle fiber8.  Since then, a great deal of research has 
attempted to elucidate the specific roles satellite cells play in skeletal muscle, particularly in 
muscle maturation, adaptation, and repair.  During post-skeletal development, the satellite cell 
normally remains quiescent; however, satellite cell activity can be induced in response to muscle 
injury.  In fact, recent studies demonstrate that satellite cells are indeed necessary for skeletal 
muscle to undergo regeneration9-12.  These studies and others that evaluate satellite cell function 
utilize an important marker of satellite cells: paired box protein-7 or Pax7, encoded by the PAX-
7 gene. Pax7 itself is a transcription factor that plays an integral role in myogenesis and regulation 
of muscle precursor cell proliferation. It is considered the requisite marker for satellite cell 
identification, and Pax7 genetic manipulation is utilized to assess specific myogenic function.  
Pax7 satellite cells, however, are not the only cell type that displays myogenic potential6,13,14.  For 
example, mesoangioblasts, pericytes, Pax3, SK-34, CD45+/Sca1+, muscle side population, and 
PW1+/Pax7 interstitial cells have all been implicated in contributing to the myogenic cell pool.  
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However, formation of functional skeletal muscle in vivo utilizing most of these progenitors 
appears to require some level of Pax7 expression15-17. Ultimately, the complexity of the myogenic 
pool allows for diversity in tissue engineering strategies. Isolating Pax7-positive satellite cells for 
tissue engineering applications, however, is complicated by the heterogeneity and diversity of 
cells in this larger myogenic population.  
Skeletal muscle tissue engineers choose to focus on isolating Pax7 satellite cells because 
of the proven regenerative potential of this specific population. While the variety of cell types 
detailed above display some degree of myogenic potential, the satellite cell has been identified 
as the primary source of regeneration in damaged skeletal muscle6,18. Quiescent satellite cells are 
activated in response to injury and progress toward a committed myogenic lineage, with a sub-
population returning to quiescence to maintain the progenitor pool. Those satellite cells induced 
to a myogenic lineage are often referred to as myogenic precursor cells or myoblasts, 
characterized by their expression of the transcription factors myogenic differentiation 1 (MyoD) 
and myogenic regulatory factor 5 (Myf5)19. Following myoblast proliferation and differentiation, 
the myoblasts fuse with damaged fibers and promote regeneration.  
In addition to extensive research into the satellite cell itself, a great deal of emphasis has 
focused on the microenvironment or “stem cell niche” which has been shown to be highly specific 
to and influential for satellite cell behavior and myogenic function20,21.  The niche constituents 
include the satellite cell itself along with the surrounding extracellular matrix, vascular and neural 
networks, surrounding cells, and various diffusible molecules. This dynamic environment 
presents a unique challenge for engineered tissues in vitro because of the constant 
communication between the satellite cell and its niche in vivo. The growth factors and signaling 
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pathways dictating cellular regeneration are in constant flux, increasing the complexity of 
emulating myogenesis in vitro.  Therefore, understanding the intrinsic and extrinsic signaling 
factors that influence the niche has been a priority for developing therapeutics in regenerative 
medicine22, and similarly, strategies for muscle tissue engineering must aim to replicate the ideal 
conditions for skeletal muscle tissue repair. 
Since the first skeletal muscle tissue engineering experiments by Vandenburgh and 
colleagues in 198823, the field has rapidly advanced to include a variety of techniques to enhance 
myogenesis and tissue regeneration. Although technologies include either scaffold materials 
ranging from acellularized tissues24,25 to collagen and fibrin hydrogels26,27 or a scaffold-free 
approach28,29, the vast majority of these techniques utilize satellite cells as the cell source for 
muscle engineering. The complex satellite cell biology shows that isolating and culturing satellite 
cells presents a unique challenge. In particular, engineered skeletal muscle tissue requires a large 
quantity of isolated satellite cells with high purity. Engineered tissues to date have produced 
minimal force in comparison to healthy muscle, and the suspected cause of this disparity is 
decreased muscle fiber content and maturity28,30,31. As such, it is essential to maximize the 
myogenesis in engineered skeletal muscle tissue by isolating a pure satellite cell population. This 
process should result in both increased fiber content and improved functionality. Unfortunately, 
current methods for isolating satellite cells cannot yield both the population size and myogenic 
purity required by tissue engineers. It is instead necessary to combine these isolation techniques 
with additional purification methods, followed by controlled proliferation and induction 




Single Fiber Explant Culture 
First described in 1986 by Bischoff and colleagues, techniques to explant and isolate 
individual muscle fibers have since been modified to isolate rat satellite cells32. In the original 
work, digestion of a dissected muscle and tendon in crude collagenase type I allowed liberation 
of individual myofibers. This procedure was found to be most successful after the fractionation 
of the collagenase, which enhanced the ability to remove the basal lamina from fibers and 
exposed the satellite cells. Because the separated fibers did not adhere to a standard polystyrene 
tissue culture substrate, a coating of either collagen or clotted chicken plasma was applied.  This 
discovery opened an entire field of study on the use of similar substrates to promote adhesion 
of the satellite cells during the tissue engineering of skeletal muscle. Separation of individual 
fibers in this manner induced cellular signals of muscle injury, prompting satellite cell 
proliferation up to 4 days in vitro.  Satellite cells remained attached to their respective fibers, 
however, so further study was needed to isolate the satellite cells from their basal lamina niche. 
A modification of the Bischoff system by Rosenblatt and colleagues yields a pure 
population of both rat and mouse satellite cells from single fiber explants33. Following enzymatic 
digestion and separation, each fiber is plated individually with the aid of a dissecting microscope. 
A schematic of this protocol is shown in Figure 2. Central to this approach, satellite cells dissociate 
from their fibers and adhere to the tissue culture plate. Matrigel, an extract of basement 
membrane proteins derived from Engelbreth-Holm-Swarm mouse sarcoma cells, was used as a 
substrate coating in this case because it allowed both satellite cell attachment and subsequent 
removal of the fiber. As a result, when the fibers are removed from the plate after 3-4 days in 
vitro, a highly myogenic adherent cell population remains for further expansion and study. Using 
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this method, up to 300 satellite cells can be obtained per fiber, with potential for approximately 
300-fold expansion to 100,000 myogenic cells33. 
 
Since its introduction and subsequent modification, the single fiber method for isolating 
satellite cells has remained relatively unchanged. A much more detailed procedure was published 
in 2010 by Conboy and colleagues, but the basic steps are consistent with previously published 
papers34. This approach is generally accepted to yield the purest satellite cell populations, 
approximately 95% or higher33 but has serious limitations in that dissecting individual muscle 
fibers is a highly precise and time-consuming task. Furthermore, although only individual fibers 
are needed for the final explant culture step, this protocol dictates removal of the entire muscle 
to avoid fiber damage. Because of its ability to yield satellite cells in vitro with high purity, single 
fiber isolations serve as powerful tool for the study of satellite cell biology, but the relatively low 




Figure 2. Single fiber explant culture for isolation of satellite cells. This technically challenging and labor-
intensive isolation method yields a highly pure, but relatively small satellite cell population. The desired muscle is 
dissected and enzymatically dissociated until individual myofibers can be removed under a microscope. These 
fibers are then cultured for several days, allowing for egress of satellite cells onto the culture substrate. When the 





To increase overall yield, many researchers use an enzymatic digestion of whole muscles 
to isolate satellite cells (Figure 3)35,36. This technique was also pioneered in the rat by Bischoff 
and colleagues37, with significant modifications by Rando and Blau in the mouse36. Using this 
approach, muscle tissue is dissected and dissociated into a single cell suspension. Initially, all 
visible tendon and connective tissue is removed from the harvested muscle to maximize final 
myogenic purity. It is common for researchers to use a combination of enzymes to specifically 
digest the various skeletal muscle extracellular matrix components and “release” cells of interest. 
However, a rigorous enzymatic digestion process will also liberate a population of fibroblasts, 
leading to a diluted satellite cell suspension. Current methods have identified various 
combinations of trypsin, pronase, dispase, and several collagenases as optimal mixtures37-39, and 
a study by Tebbets and colleagues highlights this variety in proteolytic enzymes used across the 
field40. Several studies have compared the relative efficacy of these enzymes41-43. It is believed 
that a mixture of collagenase and dispase minimally affects cell surface antigens, allowing for 
easier future enrichment of isolated cells41. On the other hand, pronase may inhibit survival and 
proliferation of non-myogenic cells and yield a purer isolated satellite cell population42. 
Ultimately, direct comparison suggests that these enzymes are all suitable for liberation of 
satellite cells, assuming one uses the correct duration of enzymatic digestion43.  Following 
digestion, debris is removed from the suspension by filtration, and isolated cells are seeded for 
proliferation and differentiation.  
Selection of the proper substrate adhesion protein is important at this stage in promoting 
satellite cell attachment. Collagen, polylysine, fibronectin, Matrigel, and laminin are commonly 
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used as adhesion proteins31,38. Several studies have compared the efficacy of different adhesion 
proteins in preferentially promoting satellite cell adhesion, proliferation, and differentiation44-49 
(Table 1). As these compiled results show, no specific adhesion protein has been identified as 
ideal for culturing satellite cells, but it is clear that the adhesion proteins described in Table 1 
(fibronectin, Matrigel, gelatin, and laminin) promote increased attachment and proliferation 
relative to uncoated polystyrene tissue culture plastic or alternative proteins (polylysine and 
collagen types 3 or 4)38,44.  
 
Following isolation, characterizing the purity of the final cell population is essential when 
engineering skeletal muscle. While flow cytometry, described in detail below, certainly presents 
a high-throughput technique for identifying the various cells in a heterogeneous population, the 
use of cytochemistry for identifying myogenic and non-myogenic cells is a more traditional 
approach. Using markers of satellite cell activation, it is possible to stain isolated cells for 
canonical proteins that identify not only their myogenicity but also their state in the regenerative 
process. It is known that quiescent and activated satellite cells express Pax720,50. Following 
 
Figure 3. Enzymatic dissociation for isolation of satellite cells. This isolation method can yield a large satellite 
cell population suitable for tissue engineering purposes, but requires additional purification to remove non-myogenic 
cells. A muscle biopsy is mechanically and enzymatically digested to yield a single cell suspension. The resulting 
heterogeneous population contains a mixture of satellite cells, fibroblasts, hematopoietic cells, and several other 
types. As a result, it is often necessary to enrich the myogenic satellite cell population through the purification 




activation, identified by Myf5 upregulation and MyoD expression, the satellite cell becomes a 
myogenic progenitor or myoblast. By examining cultured satellite cells for Pax7, Myf5 and MyoD, 
it has been determined that removal of satellite cells from their niche during isolation 
immediately leads to their activation, and that a minimal quiescent population remains in vitro38. 
MyoD staining can therefore be used to identify proliferating satellite cells as soon as 24 hours 
post-isolation38.  
 
As regeneration continues, fusion of myoblasts and terminal differentiation occurs, 
accompanied by expression of myogenin, desmin, and c-met. Desmin, in particular, has often 
been utilized as an indicator of proliferating myogenic cells at time points ranging from 30 hours 
to several days post-isolation36,38.  After myotube formation, typically occurring around 7 days 
post-isolation but varying with seeding density and onset of differentiation, neonatal or 







Wilschut et al. 201049 




Matrigel, Laminin Matrigel, Laminin 
Boonen et al. 200948 





Maley et al. 199546 
Gelatin, Collagen-4, 
Fibronectin, Laminin 
- - Matrigel 
Doumit et al.199244 Gelatin, Collagen-3, Fibronectin - Gelatin Gelatin 
Dodson et al. 199047 
Gelatin, Collagen-1, Collagen-
4, Fibronectin, Laminin, Poly-L-
lysine, Poly-D-lysine 
Fibronectin Gelatin Gelatin 
Table 1. Comparison of adhesion proteins for isolated satellite cells. Overall, fibronectin, Matrigel, gelatin, and 
laminin seem ideal for culturing satellite cells, and these four adhesion proteins are most commonly used. From a 
tissue engineering perspective, Matrigel has limited clinical relevance because it is derived from a cancer cell line. 
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embryonic myosin heavy chain isoforms can be used to identify nascent muscle. By following 
these previously established markers to identify myogenic cells within the overall isolated 
population, it is possible to evaluate the overall success and purity of the isolation process. 
Using such characterization methods, it has been determined that the final cell 
suspension isolated via the enzymatic dissociation method is significantly less myogenically pure 
than the single fiber isolation method. The isolates are contaminated by a small population of 
hematopoietic and neural cells, and connective tissue fibroblasts form the majority of the non-
myogenic population. This fibroblast fraction plays an essential role in myogenesis through a 
reciprocal interaction with the proliferating satellite cells, but in large numbers can inhibit 
regeneration11,51. On the other hand, fibroblasts proliferate more rapidly than satellite cells7,38, 
and this non-myogenic population can potentially overwhelm proliferating myogenic cells if too 
numerous initially. As a result, knowing the starting cell populations and monitoring the 
interaction between isolated satellite cells and fibroblasts is essential to understanding growth 
of muscle tissue during skeletal muscle tissue engineering. For reference, yields of approximately 
10,000 satellite cells per 100mg of digested muscle have been reported, with potential 
proliferation to 10 million cells35. Due to the ease at which significant volumes of muscle can be 
harvested, the potential for obtaining relevant numbers of satellite cells for tissue engineering is 
much larger with this method than through the single fiber isolation method.  As a result, tissue 
engineers utilize this enzymatic dissociation method preferentially for high cell volume 
requirements. However, because of the lower myogenic purity, supplemental purification steps 
are often necessary to increase regenerative potential of the isolated satellite cells, and such 




One of the most common methods for rapidly purifying satellite cells from a muscle 
homogenate is a selective pre-plating method published by Richler and Yaffe52. Following 
enzymatic dissociation, this serial pre-plating technique has been used to enrich the isolated 
myogenic cell population. Instead of seeding isolated cells directly onto a substrate coated with 
adhesion protein, the cell suspension is distributed onto uncoated tissue culture plastic for a 
period ranging from 15 minutes to 24 hours36,40. Fibroblasts and epithelial cells present in the 
muscle homogenate rapidly adhere to the tissue culture plastic, and the satellite cells remaining 
in suspension can be collected in the non-adherent cell population35,52. Using multiple iterations 
of pre-plating to enrich the non-adherent cells, a purified myogenic cell population can be 
obtained prior to the final seeding.  Previous work has demonstrated increased purification with 
each subsequent step finding a 94% myogenic purity following six pre-plate steps over the course 
of 6 days53.  
The technical simplicity of using pre-plating as a purification step following enzymatic 
dissociation is certainly an advantage. However, during the pre-plating process, some myogenic 
cells inevitably attach either to the tissue culture plastic or to the adherent fibroblasts and are 
lost. Careful control of the pre-plate time is thus necessary to balance retention and purification. 
The major drawback of this technique is its time-consuming nature. Satellite cells and myoblasts 
have a limited potential for proliferation, because isolation typically leads to their activation, 
terminal differentiation, and loss of the potential for self-renewal38. As a result, maximizing the 
in vitro proliferative capacity of these myogenic cells is essential. Any time spent purifying 
through pre-plating, however, decreases this limited capacity for proliferation. Additionally, pre-
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plating is limited by the potential for myogenic and non-myogenic cell populations to vary 
significantly in the final cell suspension. Although the purity of isolated cells has certainly been 
increased, the degree of improvement is inconsistent, and final purity remains unknown without 
additional analysis of cellular content. For tissue engineers, knowing the final myogenic purity is 
essential for consistent tissue fabrication. Fluorescence activated cell sorting (FACS) and 
magnetic activated cell sorting (MACS) have been used to evaluate the success of the pre-plating 
process, leading researchers to consider whether they can be used to skip pre-plating and 
immediately sort instead54,55. 
FACS - Fluorescence Activated Cell Sorting 
Among the sorting techniques that may be applied to the isolation of satellite cells, FACS 
shows promise due to its efficiency in sorting large populations of cells. This technique has been 
used extensively as both a diagnostic and research tool to obtain information rapidly about 
heterogeneous cell populations including cell number, relative cell size, and cell viability. FACS 
operates through laser-based identification of fluorophore-conjugated cell markers and applied 
electrical charges to physically separate individual cells. The use of FACS in satellite cell 
purification, however, is complicated by the absence of a definitive surface marker. Early work 
on myoblast isolations by the Blau laboratory demonstrated that semi-pure primary mouse 
myoblasts could be isolated using FACS and antibodies to α7 Integrin alone24. Recent work has 
focused on improving the purity of isolated satellite cells by using a combination of markers to 
identify and isolate satellite cells from other muscle-derived cells, as described in Table 242. 
Recently, Pasut et al. demonstrated successful FACS isolation of satellite cells using a 
combination of positive markers α7 Integrin and CD34 with negative markers CD45, CD31, CD11b, 
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and Sca-156. Likewise, Sherwood et al. demonstrated similar FACS isolation of myogenic cells 
using positive markers CXCR4 and β1-integrin and negative markers CD45, Sca-1, and Mac-1, and 
cell purity was confirmed by growing the sorted cells into myotubes in cell culture57. Because of 
the heterogeneity of the satellite cell population, with certain sub-populations displaying unique 
surface marker profiles, various additional marker combinations specific to satellite cells have 
been identified58,59.  
 
Consistent with the work described above, Bosnakovski et al. identified CD34 as a positive 
marker and CD45 as a negative marker for satellite cells sorted from a Pax7-ZsGreen+ mouse60. 
Bosnakovski’s work also found that only half of the sorted satellite cells expressed CXCR4, in 


















Montarras et al. 2005146 Pax3GFP/+ Satellite Cells CD34 CD45, Sca-1 - 






Asakura et al. 200259 Satellite Cells CD34 CD45, Sca-1 - 
 
Muscle Side Population 
Cells 
- - CD45, Sca-1 
Jankowski et al. 200161 
Proliferating Muscle-
Derived Stem Cells 
- CD45, c-Kit CD34, Sca-1 
Table 2. Prospective surface markers for isolation of satellite cells. Due to the heterogeneity of the myogenic 
pool, FACS targeting different cell populations has identified various surface marker combinations. The most 
consistent trend is the use of CD34 as a positive marker, with CD45 and Sca-1 as negative markers. In several 
cases, these and other markers were identified on a unique subset of the isolated population, and they are labelled 




partial disagreement with Sherwood’s work. This finding again suggests the presence of unique 
sub-populations within the larger satellite cell pool, potentially complicating the sorting process. 
A similar heterogeneity within the satellite cell pool also occurs with injury to the muscle prior to 
isolation, evident when sorting yields Sca-1 positive, rather than negative, satellite cells. Similar 
variation in satellite cell surface markers has been demonstrated when examining CD34 and Sca-
1 expression in myogenic cells in vitro61. In particular, distinct sub-populations, both positive and 
negative for CD34 and Sca-1, were found within the heterogeneous myogenic cell population 
over a period of 6 days in vitro. When examined together, these studies illustrate the difficulties 
in purifying satellite cells presented by the heterogeneous surface marker profiles across the 
overall isolated population. Ultimately, FACS has proven successful in purifying myogenic cells 
from a heterogeneous cell population isolated in a mouse model, illustrated in Figure 4. Such 
plots also demonstrate the considerable technical expertise required to differentiate the sub-
populations typically overlapping each other. Although researchers have utilized a wide variety 
of surface markers, the common trend across these strategies is the use of CD34 as a positive 
marker and CD45 and Sca-1 as negative markers. However, as tissue engineers seek to use larger 
animal models, study of these heterogeneous surface markers present in the myogenic pool will 
be required for each new species. Again, while satellite cell sorting with FACS has proven 
effective, potential damage to cells or alteration of their proliferation during the sorting process 
remain significant drawbacks to the use of FACS in muscle tissue engineering. The electrical 
charge applied to separate cells requires a substantial voltage, and though the satellite cells 
typically survive this perturbation, it is thought that gene expression may be altered62.  
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Specific studies to examine the effects of FACS on satellite cell viability and subsequent 
proliferation in vitro have not been conducted, so it remains to be seen if sorted cells are still 
suitable for tissue engineering purposes. The use of FACS in isolating human embryonic stem 
cells, however, led to decreased viability63, and destabilization of the membrane was observed 
in sorted spermatozoa64.  Unless such damaging effects can be avoided in the case of satellite 
cells, skeletal muscle tissue engineers may choose not to use FACS to purify isolated cells and 
instead use it only for characterization. 
 
 
Figure 4. Example methodology for FACS purification of satellite cells. Dot plots representing the 
sequential gating strategy used to identify satellite cells from a heterogonous muscle sample based on: (a) Side 
Scatter (SSC) and Forward Scatter (FSC), (b) Doublets discrimination, (c) PE- gating to remove CD45 and 
CD11b blood lineage cells, Sca-1 mesenchymal progenitors, and CD31 endothelial cells, (d) Hoechst staining 
for live (Hoechst+) and dead (Hoechst−) cells, (e) Integrin α7+ and Sca-1- (Lin−) gating, and finally (f) Integrin 
α7+ and CD34+ gating to sort the population defined as satellite cells. As the plots above illustrate, unique 
populations are rarely completely distinct, and substantial technical expertise is necessary to design such gating 




MACS - Magnetic-Activated Cell Sorting 
Magnetic-activated cell sorting (MACS) offers an alternative method for satellite cell 
sorting. Commonly utilized in immunology, neuroscience, and cancer research, MACS operates 
by incubating cells with antibodies for specific markers of interest conjugated to magnetic 
microbeads. Because it similarly relies on sorting by antigen expression, MACS suffers from the 
same primary limitation as FACS—the lack of a definitive surface marker prevents direct sorting 
of satellite cells, and some combination of markers must instead be used. Research by the Blau 
laboratory demonstrated that semi-pure mouse myoblast populations may be isolated using 
MACS technology to select for α7 Integrin+ cells, with similar purification levels as found with 
FACS55. Although MACS has been used in some cases to purify CD56 positive satellite cells65, 
direct comparison of pre-plating and MACS indicated much greater purification using the pre-
plating technique54. From these studies, it is clear that multiple markers are likely needed to 
isolate a highly pure population.  
An additional complication associated with MACS sorting is the magnetic labelling. While 
the antibody-marker conjugation used in FACS is certainly a modification of the target cells, with 
antibody binding potentially activating or blocking signaling pathways associated with the target 
surface receptor62, the attachment of magnetic microbeads is a far more significant alteration66. 
From a tissue engineering standpoint, concerns arise regarding implantation of cells that may 
retain attached or internalized microbeads. As a result, MACS may be limited for application in 
tissue engineering to negative sorting, the removal of cell types other than that of interest, 
resulting in a semi-pure cell population. This technique has been demonstrated by using MACS 
to remove CD45+ cells from a cell isolate67. Until methods for magnetically sorting satellite cells 
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has been improved and concerns about magnetic microbead retention have been resolved, 
MACS may not provide a realistic cell sorting approach for tissue engineering.  
Summary 
Considerable effort has been dedicated to isolating and purifying satellite cells. Because 
of these advances, several powerful tools are available to tissue engineers. Single fiber explant 
culture isolations yield small populations with high purity, whereas enzymatic dissociation 
isolates a mixture of myogenic and non-myogenic cells with a need for additional purification. 
Pre-plating is the most common method for purification and has proven effective, but it 
ultimately lacks a quantitative measure of the final myogenic cell population. FACS and MACS 
have also been considered, with FACS potentially providing the ability to both sort and 
characterize isolated cells. Further understanding of satellite cell surface markers may make FACS 
an increasingly viable alternative; however, the need for labelling and the potential for alteration 
during the sorting process ultimately limit FACS and MACS. 
As researchers seek to translate engineered skeletal muscle technologies from small 
animal models to larger animals and eventually humans, more efficient and reliable isolation 
methods will become essential. Techniques for increasing myogenic cell proliferation and 
inducing differentiation in vitro by controlling culture conditions and seeking to recapitulate the 
satellite cell niche are being developed to utilize isolated satellite cells maximally, but the scaling 
up process could exceed these capabilities.  It is expected that rapid development will continue 
in the areas covered in this sub-chapter since they will help translate tissue engineering of 
skeletal muscle into a viable clinical treatment. 
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Growth Factors and Skeletal Muscle Tissue Engineering 
The text and figures in this sub-chapter were originally published with the following 
citation: Syverud BC, VanDusen KW, and Larkin LM. “Growth factors for skeletal muscle tissue 
engineering.” Cells Tissues Organs 202: 169 (2016)68. Excerpts from this article have been 
included with permission from the publisher, S Karger AG.  
Proposed applications for tissue-engineered skeletal muscle include implantation as a 
graft material for repair of traumatic damage30,69, recapitulation in vitro of native development 
and regeneration for detailed physiological study or pharmaceutical testing27, and use as 
biomechanical actuators70,71. In all cases, mimicking the complex structure and function of 
skeletal muscle in vivo is an essential consideration. To date, however, engineered tissues have 
been characterized by a neonatal phenotype in terms of vascularity, force production, and 
structural maturity26,29. Without major advances, especially in vascularization, use of engineered 
muscle as a graft material will be severely limited. Implantation of engineered skeletal muscle 
into an in vivo regenerative environment, however, has promoted development towards the 
adult phenotype24,72, and several recent studies have attempted to utilize key chemical and 
mechanical stimuli to improve the maturity of these engineered muscles in vitro 65,73. This review 
focuses on important in vitro biochemical stimuli, summarizing the current state of the art in 
growth factors utilized for skeletal muscle tissue engineering.  
 Skeletal Muscle Development During Embryogenesis 
Before attempting to describe the ideal in vitro biochemical environment for engineered 
skeletal muscle, it is necessary to understand the in vivo environment tissue engineers seek to 
emulate. During embryogenesis, morphogen gradients control patterning of the developing 
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tissues. Following germ layer formation in the pre-patterned embryo, localized variations in gene 
expression and signaling gradients prompt condensations of the paraxial mesoderm into somites 
(Figure 5)74. Genes in the Notch and Wnt pathways prompt somitogenesis in concert with 
spatiotemporal gradients of fibroblast growth factor (FGF) and Wnt proteins. The most dorsal 
section of the somite becomes the dermomyotome, from which the majority of skeletal muscles 
are derived. Myogenesis is initiated as the Pax3+ progenitor cell pool present in the somite 
delaminates and progressively establishes the primary myotome75. Members of the Wnt family 
of proteins again play a central role in this process. Through binding to Frizzled receptors, Wnt 
signaling activates the β-catenin/TCF complex and induces somite patterning and expression of 
the myogenic transcription factors Pax3 and Myf574. A small subset of the progenitor cell pool 
migrates into the myotome, proliferates, and then terminally differentiates into myoblasts.  In 
turn, the terminally differentiated myoblasts fuse with each other to form the first 
multinucleated myotubes and primary myofibers76. This stage of myogenesis is primarily 
regulated by the canonical myogenic regulatory factors: Myf5, MyoD, and myogenin. Sonic 
hedgehog (Shh), released from the notochord and floor plate of the neural tube, promotes Myf5 
expression and commitment to the myogenic lineage74,76. With the establishment of innervation, 
the remaining cells from the progenitor pool differentiate into myoblasts and fuse to form 
secondary myofibers. In addition, a subset of skeletal muscle progenitor cells start to co-express 
Pax3 and Pax7, becoming post-natal progenitor cells often referred to as satellite cells8,77. These 
satellite cells are not activated during embryonic myogenesis and remain as a reserve pool for 
post-natal muscle growth and regeneration. Bone morphogenic proteins (BMPs), a sub-class of 
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the transforming growth factor-beta (TGFβ) superfamily, serve to preserve this progenitor pool 
by inhibiting Myf5 and MyoD expression while upregulating Pax3.  
 
In summary, myogenesis during embryonic development is primarily regulated by Myf5, 
MyoD, and myogenin76, but several molecular signals and growth factors interact with these 
myogenic regulatory factors. Wnt and FGF gradients direct initial somitogenesis. Subsequently, 
Shh and Wnt signaling lead to specification and expression of Myf5. Additionally, TGFβ is known 
to act through serine-threonine kinase receptors, activating SMAD proteins inhibiting Myf5 and 
MyoD induction. As a result, the onset of skeletal muscle formation is delayed and the myogenic 
progenitor pool is preserved. Finally, FGF acts as an antagonist to TGFβ in regulating the 
equilibrium between renewal and differentiation of progenitor pool. Specifically, FGF 
upregulates Myf5 and MyoD, promotes activation of progenitors in the myogenic lineage78, and 
begins the transition to post-natal skeletal muscle development.  
 
 
Figure 5. Initial skeletal muscle formation during embryogenesis. (A) Development of the somite and 
subsequent establishment of the myotome. (B) Regulation of progenitor cell renewal and differentiation by myogenic 




Post-natal Skeletal Muscle Development 
Post-natal skeletal maturation and lengthening of skeletal muscle relies on the 
contribution of nuclei and contractile proteins by satellite cells to keep pace with the growing 
skeleton and to mature in structure. This process is characterized by addition of new sarcomeres 
along the length of each fiber, establishment of myotendinous junctions, and the transition in 
myosin heavy chain (MHC) expression from embryonic to adult fast and slow isoforms75,79. 
Satellite cells provide the nuclei required to regulate this continued growth. Until activated, 
satellite cells remain quiescent under the basal lamina of skeletal muscle fibers and are 
characterized by the expression of Pax78. The surrounding stem cell microenvironment or niche, 
composed of extracellular matrix, vascular and neural networks, neighboring cells, and growth 
factors, is highly influential on myogenic function (Figure 6)20,80. In response to a complex series 
of signals, satellite cells are activated and progress toward a committed myogenic lineage, with 
a sub-population returning to quiescence to maintain the progenitor pool. As in embryonic 
development, Notch signaling and Wnt proteins act as essential regulators of post-natal 
maturation of the satellite cell. In particular, Wnt3a signaling promotes satellite cell activation 
and differentiation, whereas Wnt7a induces self-renewal and maintenance of the satellite cell 
pool74. Mammalian (or mechanistic) target of rapamycin (mTOR) also plays a key role in 
mediating post-natal satellite cell activation, proliferation, and differentiation. Although more 
commonly associated with skeletal muscle hypertrophy and homeostasis, mTOR has recently 
been shown to regulate satellite cell activity and myogenesis by upregulating expression of Pax7, 
Myf5, MyoD, and myogenin81.   
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Additionally, several growth factors stimulate quiescent satellite cells. Hepatocyte growth 
factor (HGF) is present in inactive form in the extracellular matrix adjacent to satellite cells79. 
When released due to injury or length damage, HGF is thought to bind c-met receptors present 
on quiescent satellite cells, leading to their activation. Similarly, members of the FGF family are 
present in the satellite cell niche and bind to quiescent satellite cell receptors following FGF 
release76,79. After activation via growth factors such as HGF or FGF, those satellite cells induced 
to a myogenic lineage are often referred to as myogenic precursor cells or myoblasts, 
characterized by their expression of canonical myogenic transcription factors MyoD and Myf5. 
Following their proliferation and differentiation, the myoblasts fuse with maturing muscle fibers 
and promote protein synthesis and muscle growth. Connective tissue fibroblasts in the 
extracellular matrix have been shown to interact with satellite cells throughout this stage, with 
reciprocal signaling between the two cell types prompting increased proliferation of both82. 
 
Figure 6. Growth factor signaling in skeletal muscle regeneration. The microenvironment surrounding the 
satellite cell (SC) niche regulates repair of skeletal muscle damage. Resident immune cells, extracellular matrix 
(ECM), and capillary and neural networks compose this niche. This schematic describes a simplified process 




Furthermore, expression of the transcription factor Tcf4 by connective tissue fibroblasts 
intrinsically regulates the maturation of MHC isoforms through β-catenin activation51,76. In 
conclusion, post-natal skeletal muscle development depends on activation and myogenic 
differentiation of satellite cells. Although the satellite cell pool is considered heterogeneous, 
several common signaling pathways play essential roles in this myogenic lineage, with HGF and 
FGF as the primary growth factors involved.  
Skeletal Muscle Homeostasis 
Once skeletal maturation is complete, skeletal muscle homeostasis is maintained through 
hypertrophy and atrophy. Hypertrophy and regeneration are primarily regulated by a signaling 
pathway initiated by insulin-like growth factor 1 (IGF1)78. Whether expressed by muscle cells in 
response to injury and exercise, secreted by macrophages and endothelial cells with 
inflammation, or supplied by the circulatory system in the blood, IGF levels increase rapidly in 
preparation for protein synthesis83. Following IGF1 binding, an intracellular cascade mediates its 
effects (Figure 7)84,85. Among these intracellular signals, Akt, or protein kinase B (PKB), plays an 
essential role86. To promote protein synthesis and hypertrophy, Akt indirectly activates mTOR 
while simultaneously inhibiting glycogen synthase kinase 3b (GSK3b). At the same time, Akt 
prevents protein degradation and muscle atrophy by blocking the FoxO family of transcription 
factors87. Myostatin, a member of the TGFβ family predominantly expressed in skeletal muscle, 
conversely functions as a potent cytokine for the inhibition of muscle growth and induction of 
muscle atrophy. Following activation and release from the extracellular matrix, myostatin 
activates Smad2/3 and TAK1/P38 MAPK signaling cascades, leading to upregulation of Atrogin-1 
and muscle RING-finger protein-1 (MuRF-1) and subsequent proteolysis88. Both IGF1 and 
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myostatin, along with their downstream effectors, have been targeted for therapeutic use in 
vivo83,87, and it is expected that similar benefits will translate to engineered skeletal muscle.  
         
External to the IGF/Akt/mTOR signaling pathway, several growth factors have been 
examined due to their effects on myogenic progenitor cells implicated in skeletal muscle growth 
and development. As in embryonic development, TGFβ inhibits progression of muscle precursor 
cells87,89. In contrast, HGF, FGF, and platelet derived growth factor (PDGF) have all been 
associated with muscle repair and hypertrophy90,91. As in post-natal development, HGF is 
 
Figure 7. Central pathways to regulation of skeletal muscle hypertrophy and 
atrophy. The hypertrophic effects of IGF-1 have been widely documented.  Binding 
of IGF-1 to its receptor leads to release of Akt to the cytosol and activation of mTOR 
and protein synthesis. Myostatin (MSTN) and TGF-β control skeletal muscle 
atrophy. When activated, these cytokines trigger a signaling cascade leading to 
upregulation of Atrogin-1 and MuRF-1 and protein degradation. Adapted from 




released from the extracellular matrix with injury to prompt satellite cell activation and 
proliferation via p38 MAPK and PI3K83. FGF serves a similar purpose, mainly stimulating 
proliferation of satellite cells. After release from activated platelets and macrophages, PDGF 
again promotes myogenic proliferation, in addition to angiogenesis. Interestingly, these three 
growth factors (HGF, FGF, and PDGF) all have an inhibitory effect on myogenic differentiation83,91. 
Overall, it is evident how various growth factors are intricately involved in these native pathways 
controlling the development, growth, and regeneration of skeletal muscle. Their interplay with 
the canonical myogenic regulatory factors is evident in the activation and proliferation of 
myogenic progenitors, terminal differentiation to myoblasts, and up- or down-regulation of 
protein synthesis and degradation.  
Growth factors for skeletal muscle tissue engineering 
Because of the difficulties associated with isolating and purifying satellite cells, it is 
essential to maximize the myogenic potential of these cells in vitro. In addition, isolated satellite 
cells can only be expanded to a limited extent, because myogenic potential rapidly decreases 
after isolation33,92. This behavior can at least partially be explained by the fact that fibroblasts 
and other non-myogenic cells in the isolated population double every 18 hours, much more 
rapidly than the approximately 24 hours for satellite cells7,38. Several studies have demonstrated 
the ability to expand isolated muscle progenitor cells in vitro for up to 50 population 
doublings36,93. However, examination of myogenic potential over this expansion period 
demonstrated a steady decline in Pax7, MyoD, and desmin expression, beginning at over 90% 
and decreasing to approximately 55% by the third passage94. Furthermore, 
immunocytochemistry for 5-bromo-2’-deoxyuridine-5’-monophosphate (BrdU) showed 60% 
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positive staining at the time of isolation but steadily decreasing values with each subsequent 
passage, indicating declining activation and proliferation of isolated satellite cells with increased 
time in vitro. With this understanding of in vitro satellite cell behavior, it is essential to maximize 
proliferation of isolated satellite cells before myogenic potential drops or faster proliferating 
populations begin to take over the culture. Thus, comprehensive study has determined optimal 
conditions for promoting proliferation and inducing differentiation of satellite cells.  
 Tissue engineers have used this understanding of growth factors and their role in 
myogenesis to direct techniques for the fabrication of skeletal muscle. To date, tissue engineering 
technologies utilize either scaffold materials ranging from decellularized tissues95,96 to collagen 
and fibrin hydrogels26,27,97 or opt for a scaffold-free approach28,29,72 to promote the development 
of an extracellular matrix (ECM) for subsequent muscle tissue. The success of these techniques 
ultimately depends on the in vitro cultivation of isolated primary muscle precursor cells for the 
development of mature muscle cells within the ECM. The typical techniques for culture of these 
myogenic cells involves an initial proliferation phase, to allow cell numbers to expand to a 
sufficiently large population, followed by differentiation and fusion into myotubes and 
maturation to myofibers98. Detailed study of growth factors known to play a role in each of these 
phases of myogenesis is thus essential to further the understanding of muscle growth in vitro. It 
is generally accepted that media rich in serum promotes initial proliferation of skeletal muscle 
stem cells to myoblasts while delaying the onset of differentiation, potentially due to large 
number of hormones and growth factors of varying concentration and potency found in the 
serum38. Dramatic changes in function and speed of contraction were recently observed between 
engineered muscles cultured in serum from the United States and from the European Union99. 
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Similarly, environmental factors in the culture media, such as glucose and antibiotic 
concentration, have been shown to alter engineered muscle phenotype and function100. In this 
study, ideal conditions for maximizing force production in tissue-engineered skeletal muscle 
involved high glucose (25mM) and an absence of streptomycin. A drastic reduction in media 
serum content following the proliferation phase triggers differentiation of the myoblast to the 
myotube, possibly due to the absence of key mitogenic components. Due to the lot-to-lot 
variations in growth factors present in the commercially available serum and the consequent 
variability in satellite cell induction and proliferation, an optimum serum formulation and the 
identity of these mitogenic components has yet to be fully defined44. To date, several growth 
factors have been implicated as potential serum components with important myogenic effects.  
As would be expected based on their in vivo influence on skeletal muscle hypertrophy 
described above, FGF, PDGF, and HGF promote activation and proliferation of myogenic 
progenitor cells and delay terminal differentiation91,101,102. The stimulatory effect of FGF on 
satellite cell proliferation has been shown to produce a two-fold increase in DNA content, relative 
to untreated cultures103. This enhanced proliferation translated to formation of larger myotubes 
and increased expression of myogenin and MHC. When added during the differentiation phase 
of the culture, however, these significant effects were not observed46,103. Similarly, the addition 
of PDGF led to a two-fold increase in DNA synthesis and improved satellite cell proliferation, but 
did not yield a significant increase in desmin expression and myotube formation46,104. In the case 
of HGF, the time between isolation of satellite cells and the onset of the cell cycle decreased from 
approximately 42-60 hours to less than 24 hours102. These results demonstrate conservation of 
the signaling pathways involved in native myogenesis in an in vitro setting, with HGF activating 
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quiescent satellite cells to begin progressing down the myogenic lineage. By combining HGF with 
either FGF or PDGF, tissue engineers may be able to maximize the replicative potential of satellite 
cells by achieving activation earlier and then increasing subsequent proliferation. Furthermore, 
HGF and FGF tend to delay terminal differentiation, allowing for extension of the window for 
satellite cell proliferation. Additionally, IGF plays a key role in all phases of satellite cell 
myogenesis, from activation and proliferation to induction of the onset of myogenic 
differentiation105,106. In one study, IGF was supplied in the fibrin gel used as a 3D scaffold to 
support the fabricated muscle tissue107. The beneficial effects of IGF addition were seen in the 
form of MyoD upregulation during initial proliferation, followed by a 50% increase in force 
production in the final engineered tissue. The functional improvement with IGF addition 
illustrates its importance in engineering skeletal muscle. In contrast, TGFβ typically has a negative 
influence on both myogenic phases in vitro, slightly suppressing proliferation and severely 
inhibiting differentiation46,91,105. TGFβ, however, can enhance contractility of engineered muscle 
by promoting collagen type I synthesis in the extracellular matrix, supporting myofiber 
development and force transmission108. As a result of these findings, it is common to supplement 
media supplied during the initial proliferation phase with HGF and FGF, prior to switching to a 
media supplemented with IGF or insulin for the induction of differentiation27,29. By adding these 
specific growth factors to influence satellite cell proliferation and differentiation, tissue engineers 






Skeletal muscle tissue engineers seek to fabricate tissue constructs to regenerate 
damaged muscle. Volumetric muscle loss is one of the primary clinical targets for engineered 
muscle due to the severity of the associated injury and the limitations to current treatments. As 
a result, recent research seeks to engineer tissue constructs that mimic native skeletal muscle 
structure and function to serve as an alternative graft source. Using the natural processes for 
skeletal muscle development and repair as models, the necessary cells and biochemical cues 
required to recapitulate myogenesis in vitro have been identified and applied for tissue 
engineering applications. Specifically, the importance of satellite cells in myogenesis makes them 
the ideal cell source for skeletal muscle tissue engineering, and common methods for obtaining 
a suitable population are described above. Following isolation of these myogenic cells, methods 
for maximizing proliferation and differentiation through control of the culture media and growth 
factors have likewise been developed.   
Recently, increasing attention has focused on recreating biophysical cues in vitro to 
promote satellite cell proliferation and differentiation, in concert with controlling media and 
growth factors. The complex nature of the satellite cell niche in vivo20,21, with signaling not only 
from chemical factors but also through physical stimuli acting on the ECM and surrounding 
microenvironment, suggests the need for similar conditions in vitro. The substrate onto which 
isolated satellite cells ultimately attach has thus been engineered to mimic native skeletal muscle 
with promising results. Instead of using stiff substrates such as polystyrene or glass, culture of 
isolated satellite cells on more compliant hydrogels promoted myogenic differentiation and 
allowed formation of advanced sarcomeric structure80,109. These hydrogels were engineered to 
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match the stiffness of healthy skeletal muscle in vivo, with Young’s Moduli of 12 kPa. Even a slight 
variation in gel stiffness to values above 20 kPa or below 5 kPa significantly reduced 
differentiation. From these results, it is clear that the biophysical stimuli transduced through the 
extracellular microenvironment play a key role in regulating satellite cell behavior in vitro.  
It naturally follows that researchers have applied additional mechanical stimuli seeking to 
further recreate the in vivo environment, commonly through custom bioreactors. These systems 
can range from aligned, cylindrical microwells designed to promote alignment and fusion into 
myotubes71, to dynamic bioreactors for providing cyclic strain either through fluid flow or 
mechanical stretch30,73. The efficacy of these bioreactors has led especially to improved satellite 
cell differentiation, but it has also brought attention to the importance of 3D tissue culture. 
Skeletal muscle tissue engineers are clearly seeking to recreate as much of the in vivo satellite 
cell niche as possible in vitro, but these efforts are inherently limited when using a flat, 2D tissue 
culture surface. The potential benefits of using a 3D culture system include improved satellite cell 
attachment and viability and myotube alignment71,110. It is expected that naturally derived 
acellularized ECM or collagen hydrogel scaffolds provide the support and 3D architecture 
necessary for satellite cell growth and development, while also avoiding potential 
biocompatibility issues25,80,111. At the same time, such scaffolds can shield the developing 
engineered tissue from the desired loading environment if degradation does not occur at the 
proper rate69. To avoid such complications, several labs including ours have developed scaffold-
free, 3D culture systems for engineering skeletal muscle tissues and implanting these tissues into 
small animal models26,28,72.  
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Such advances show promise for tissue-engineered skeletal muscle, both in terms of 
recapitulating myogenesis in vitro and restoring lost muscle function in vivo. Overall, the 
improved understanding of isolation methods and culture conditions has aided skeletal muscle 
tissue engineers in improving myogenesis. Nevertheless, engineered tissues typically exhibit an 
embryonic phenotype and produce only a fraction of the force generated by native skeletal 
muscle26,72. To address this challenge, the overall objective of this dissertation was to improve in 
vitro force production in tissue-engineered skeletal muscle to decrease its disparity relative to 
native muscle. It was expected that improving muscle fiber formation and structural 
development during the tissue engineering process would lead to such increases in force 
production. In this dissertation, novel methods for purifying isolated satellite cells, enhancing 
myogenic differentiation through steroid supplementation, and non-invasively evaluating 
metabolism and structure are described, all of which translated to improved function of tissue-






Microfluidic Sorting of Isolated Skeletal Muscle Satellite Cells 
Introduction 
Skeletal muscle has the ability to regenerate itself in response to damage3, largely due to 
the presence of potent muscle progenitor cells112. As the most abundant tissue in the body113, 
skeletal muscle requires this regenerative capacity for maintaining homeostasis and restoring 
function after injury. The resident skeletal muscle stem cell, the satellite cell, plays an essential 
role in repairing muscle damage6,50. In cases of severe injury, however, the native skeletal muscle 
repair mechanism is overwhelmed, and external intervention is indicated. A prime example is 
volumetric muscle loss (VML), defined as surgical or traumatic loss of a large volume of muscle 
tissue that leads to a functional deficit4. With VML, the ability of the damaged muscle to repair 
such a large defect through the native repair mechanism is insufficient, and fibrotic scar tissue 
instead accumulates in the defect site114. Current treatment options—free functional muscle 
transfer and composite tissue allotransplantation—involve grafting healthy muscle, innervation, 
and vasculature into the defect, but limitations such as donor site morbidity and limited tissue 
availability often prevent complete recovery111,115,116. In addition, muscular dystrophies are a 
family of inherited degenerative disorders characterized by systemic muscle weakness117-119. 
Duchenne muscular dystrophy is particularly distressing, due to its early onset and the lack of an 
effective treatment120-122. To address these clinical challenges, researchers have proposed using 
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satellite cells in cell therapy36,123-125 or tissue engineering approaches26,27,30,126,127. Although other 
cell types have been implicated as contributors to skeletal myogenesis18,57,59, recent research 
shows that satellite cells act as the primary source of regeneration of adult skeletal muscle7,50. 
Due to this tissue-specific regenerative ability, satellite cells have tremendous therapeutic 
potential.  
Obtaining a suitable population of satellite cells, however, presents a continuing 
challenge. Satellite cells are relatively few in number, only accounting for 2-7% of the nuclei 
associated with a muscle fiber8,18, and current isolation methods have difficulty yielding both the 
quantity and purity required5,38,42. As described in the previous chapter, the prevailing technique 
is to combine enzymatic isolation techniques with subsequent purification methods, such as pre-
plating or fluorescence activated cell sorting (FACS). Pre-plating is limited, however, by the 
sensitivity of the pre-plate timing and the potential for loss of myogenic cells. On the other hand, 
FACS requires modification of the cells being analyzed through the addition of exogenous dyes 
or the electrical perturbations of the sorting process itself62. Microfluidic characterization and 
sorting of fluorescently labeled skeletal muscle cells has been demonstrated as an 
alternative58,128 but is currently limited to small throughputs of hundreds of cells or less. By 
examining the existing techniques, it is clear that an efficient, label-free, high-throughput method 
for purifying satellite cells following isolation is required. 
Inertial microfluidics has the potential to fill this pressing need. The inertial migration of 
particles in a microfluidic device was first observed by Segré and Silberberg in the 1960s129 and 
recently described by Di Carlo130. The efficacy of such devices has been demonstrated for 
separating particles in fluids, and a similar approach was tested in this study to examine 
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separation of cells in suspension. Thus, the physics behind inertial separation described below 
refer to forces acting on cells rather than particles. To summarize these forces, cells in straight 
microfluidic channels experience stresses that act over the channel surface: 1) normal stress that 
yields drag forces parallel to the flow direction, 2) shear stress that yields lift forces perpendicular 
to the flow direction, and 3) a wall lift effect in opposition to the shear stress130-132. Drag forces 
accelerate cells in the flow direction along laminar streamlines. In contrast, the lift forces cause 
cell migration across streamlines. The wall lift force is directed away from the channel walls and 
decays with increasing distance from the walls. The shear lift force depends on the shear gradient 
generated by the fluid flow, resulting in forces directed away from the center of the channel. The 
combination of these lift forces focuses cells to equilibrium positions along the channel cross-
section according to the density of particles and the geometry of microfluidic channel. In a curved 
channel, centrifugal effects induce secondary flow (Dean flow) on the cross-section of the 
channel. The generated double recirculation (Dean Vortices), along with the aforementioned lift 
forces, migrate cells transversely. Cell migration is correlated to the cell size and the curvature of 
the channel, resulting in new profile of equilibrium positions which separates distinct size classes 
of cells130. In our case, a typical skeletal muscle cell isolate contains a mixture of satellite cells 
ranging from 8-13 µm34,58 and myofibroblasts ranging from 10-22 µm133,134, in addition to smaller 
populations of hematopoietic, neural, and immune cells (ranging from 6 µm for smaller red blood 
cells up to 30 µm for larger monocytes and macrophages135). 
A microfluidic device, termed “Labyrinth”, was previously designed for and applied in the 
separation of circulating tumor cells (15-25 μm) from white blood cells (7-12 μm) using inertial 
microfluidics-based separation136. It is a high throughput (1800-2500 μL/min), continuous, and 
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biomarker independent microfluidic separation technology. The design of the Labyrinth (Figure 
8), inspired by the Labyrinth in Greek mythology, incorporates 11 loops and 56 corners in a total 
channel length of 637 mm. The loops have small curvature ratios and provide enough channel 
length for complete focusing of cells, whereas sharp right-angle corners have high curvature 
ratios to further enhance focusing of smaller cells. Four separate outlets are designed to collect 
the focused individual streams of cells with differing sizes. Combining these features, the 
Labyrinth enables the separation of cells in different size classes with high efficiency. 
 
In this study, we demonstrate the power of inertial microfluidic separation for purification 
of isolated satellite cells. I hypothesized that the size difference between satellite cells and 
fibroblasts, two primary cell types obtained from chemical dissociation of muscle, would allow 
for label-free, inertial separation in a microfluidic device and that purified satellite cells could be 
used to engineer our skeletal muscle units (SMUs). Throughout the engineered tissue fabrication 
 
Figure 8. Microfluidic inertial separation in the Labyrinth device. A schematic representation of the Labyrinth 
is shown in (A). Cells in suspension enter the device at the top of the image and rapidly flow (1800 µL/min) along 
the circuitous path created by a series of curved channels. Dean forces proportional to cell size and channel 
curvature act on the cells transversely to the flow direction, separating distinct size classes of particles at the outlets 
as pictured in (B). Specifically, we intended to separate satellite cells, with a size range of 8-13 µm, from 
myofibroblasts, with a typical diameter of 10-22 µm. The Labyrinth was designed to focus the smaller satellite cells 
into Channel 1 (top), larger myofibroblasts into Channel 2 (second from top), and cell aggregates and debris into 
Channels 3 and 4 (bottom). (C) Visualization of a mixed population of Pax7+ satellite cells expressing red tdTomato 
fluorescence and Achilles tendon fibroblasts labeled with CellTracker Green fluorescent dye during sorting 
confirmed efficient separation of these two cell types based on their difference in size. 
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process described extensively in previous work29,72,108,127, Labyrinth sorted cells were compared 
to unsorted controls to assess the efficiency of the microfluidic separation process and to 
examine potential improvements in myogenic proliferation, differentiation, and overall 




All animal care procedures followed The Guide for Care and Use of Laboratory Animals137, 
according to a protocol approved by the University Committee for the Use and Care of Animals. 
Validation of the Labyrinth was performed using fluorescently labeled primary mouse cells. Pax7-
positive satellite cells expressing red fluorescence were isolated from a transgenic Pax7CreERT2-
r26-tdT mouse, provided by collaborators in the lab of Dr. Chris Mendias, Department of 
Orthopedic Surgery at the University of Michigan. To induce tdTomato fluorescence expression, 
mice were injected intraperitoneally with tamoxifen (Sigma-Aldrich, St. Louis, MO, cat. no. T5648) 
in corn oil (Sigma, cat. no. C8267) at a dose of 0.5 mg diluted to 10 mg/mL. Injections were 
repeated for five consecutive days, and cells were isolated at least ten days after the final 
injection. Mouse Achilles tendon fibroblasts were isolated from C57BL6 mice supplied by Charles 
River Laboratories Inc. (Wilmington, MA, USA) and were fluorescently labelled using CellTracker 
Green CMFDA Dye (Life Technologies, Carlsbad, CA, cat. no. C7025) according to the 
manufacturer protocol. 
SMUs were engineered using soleus muscles and bone marrow from 145-155g female 
Fischer 344 rats, supplied by Charles River Laboratories. Animals acclimated to colony conditions 
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for one week prior to any procedure and were fed Purina Rodent Chow 5001 and water ad 
libitum. Intraperitoneal injections of sodium pentobarbital (50 mg/kg for mice, 65 mg/kg for rats; 
Merck Animal Health, Madison, NJ, NADA # 119-807) were used to induce a deep plane of 
anesthesia. Supplemental pentobarbital doses were administered as required to maintain 
adequate anesthesia depth.  
Muscle Dissection and Cell Isolation 
From female Fischer 344 rats, both soleus muscles were removed under aseptic 
conditions and sterilized in 70% ethanol. All hindlimb muscles were dissected when isolating 
Pax7CreERT2-r26-tdT mouse muscle cells. The muscles were then minced using a razor blade and 
forceps, placed under ultraviolet light for 15 min in 15 mL of Ham’s F12 media (Gibco BRL, 
Carlsbad, CA, cat. no. 11765-047), and added to a dissociation solution consisting of 32U dispase 
(1.8 U/mg; Gibco, cat. No. 17105-04) and 2390U type IV collagenase (239 U/mg; Gibco, cat. no. 
17104-019) in 20 mL of Ham’s F12. The mixture was maintained at 37°C with agitation for 90 
minutes and trituration through a 1 mL micropipette every 30 minutes. The resulting suspension 
was then filtered with a 100 µm mesh filter (Fisher Scientific, Waltham, MA, cat. no. 22363549) 
prior to centrifugation. The dissociation solution was aspirated off and the cells were 
resuspended in growth medium. 
Microfluidic Device Fabrication 
The mold for the polydimethylsiloxane (PDMS) device was fabricated following a standard 
soft lithography protocol. Using a spin-coater, a negative photoresist layer of SU-8 100 
(MicroChem, Westborough, MA, cat. no. SU-8 100) was deposited onto a silicon wafer at 2450 
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rpm for 1 minute. The wafer was then soft-baked for 10 minutes at 65°C and 70 minutes at 95°C. 
A mask with the device geometry was aligned to the wafer and exposed to UV light for 20 seconds 
to cure the photoresist. Post-exposure-baking was applied for 3 minutes at 65°C and 10 minutes 
at 95°C. Next, the wafer was soaked in developer solution (MicroChem, cat. no SU-8 Developer) 
for 6 minutes and in isopropyl alcohol (Sigma, cat. no. W292907) for 1 minute to remove the 
inactivated photoresist. It was finally hard baked for 4 minutes at 150-180°C. The resulting height 
of the mold on silicon wafer was 100.0 ± 0.5 µm, and the width of the channel was 500 ± 0.5 µm. 
The flow chamber for Labyrinth was made from PDMS (Sylgard 184; Dow Chemical Corp., 
Midland, MI, cat. no. 4019862). 30 mL Sylgard polymer base and 3 mL curing agent were 
thoroughly mixed and poured onto a silicon mold. The mixture was placed into a desiccator for 2 
hours to remove air bubbles from the mixture and then heated at 65°C overnight to harden the 
polymer. The polymer was next cut into the desired shape, and punched with a needle for tubing 
insertion. The PDMS device was then bonded to standard sized glass slides via plasma surface 
activation of oxygen. The bonded device was plumbed with 0.76 mm diameter tubes (Cole-
Parmer, Vernon Hills, IL, cat. no. 06419-00). 
Microfluidic Inertial Separation 
The Labyrinth device was primed with 1% Pluronic acid solution (Sigma, cat. no. P2443) in 
Dulbecco’s Phosphate-Buffered Saline (DPBS; Fisher, cat. no. 14190144) at 100 μL/min for 10 
minutes and then incubated for 10 minutes to prevent cell clotting on channel walls. Cell samples 
in suspension were then pushed through the Labyrinth at a flow rate of 1800 μL/min using a 
syringe pump (Harvard Apparatus, Holliston, MA, cat. no. 55-2222). After 60 seconds of flow 
stabilization, the products from each of the four Labyrinth outlets were collected separately.  
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Preparation of Tissue-engineered Bone and Tendon Anchors 
As described in previous studies, bone and tendon constructs were fabricated to act as 
anchors onto which developing muscle monolayers could attach and fuse138,139. Bone marrow 
from both femurs of Fischer 344 rats was removed under aseptic conditions. Isolated bone 
marrow cells were plated in 100 mm tissue culture plates (BD Falcon, Franklin Lakes, NJ) in 8mL 
growth medium for 6 days. Growth medium was resupplied every 2 days and contained 40mL 
Dulbecco’s modified Eagle’s medium (DMEM; Gibco, cat. no. 11995- 065) with 10mL fetal bovine 
serum (FBS; Gibco, cat. no. 10437-028), 6 ng/mL basic fibroblast growth factor (bFGF; Peprotech, 
Rocky Hill, NJ, cat. no. 100-18B), and 0.5mL antibiotic-anti-mycotic (ABAM; Gibco, cat. no. 15240-
062). After achieving approximately 80% confluence, cells were passaged and replated at 310,000 
cells per plate. Following four passages, the cells were plated in 100 mm tissue culture plates at 
a density of 1.3 million cells per plate. They were allowed to grow in 8 mL growth medium for 2 
days before being shifted to differentiation medium for 3 days. Differentiation medium consisted 
of 46 mL DMEM with 3.5 mL horse serum (Gibco, cat. no. 16050-122), 0.13 mg/mL ascorbic acid-
2-phosphosate (Sigma, cat. no. A8960), 0.05 mg/mL L-proline (Sigma, cat. no. 81709), 2 ng/mL 
transforming growth factor beta (TGFβ; Fisher, cat. no. PHG9214), and 0.5 mL ABAM. Cells 
cultured with the growth and differentiation media described above differentiate to form a 
tendon monolayer. To drive cells to the bone lineage, 10 nM dexamethasone (DEX; Sigma, cat. 
no. D4902) was added to both the growth and differentiation media. Following 3 days on 
differentiation medium, the confluent monolayers delaminated from the tissue culture plate. The 
monolayers were collected, pinned in cylindrical forms into PDMS-coated dishes and fed 
differentiation medium, and left for 2 days prior to being cut into 5-mm sections to be used as 
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engineered bone-tendon anchors for construct implantation. The anchors were then pinned onto 
the developing muscle monolayers. This process is summarized below in Figure 9. 
 
SMU Formation  
  SMUs were engineered in 60 mm polystyrene plates (Fisher, cat no. 353002), and 
immunocytochemistry (ICC) was performed on 35 mm plates (Fisher, cat. no. 353001) as 
described previously72,140. Briefly, a substrate of PDMS was cured onto each plate, followed by 
coating with laminin (Natural Mouse Laminin, Gibco, cat. no. 23017-015) at 1mg/cm2. Isolated 
muscle satellite cells were seeded in muscle growth medium (MGM) at 600,000 cells per 60 mm 
 
Figure 9. Fabrication of a Skeletal Muscle Unit (SMU). To mimic the structure of 
native skeletal muscle, a multi-phasic engineered tissue was created. Bone marrow 
stem cells, isolated from the femur, were directed to form either tendon or bone 
monolayers by the culture media. After delamination and capture of these 
monolayers in 3D cylindrical form, sections of these bone-tendon constructs were 
cut and pinned onto developing muscle monolayers. Muscle monolayers were 
fabricated from the heterogeneous cell population obtained following digestion of 
the soleus muscle. Upon delamination, the muscle monolayer fused with the bone-
tendon anchors to form a scaffold-free skeletal muscle unit. 
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plate or 150,000 cells per 35 mm plate. MGM contained 30mL F-12 Kaighn’s Modification 
Nutrient Mixture (Gibco, cat. no. 21127-022), 12.5mL DMEM, 7.5mL FBS, 2.4 ng/mL bFGF, and 
0.5mL ABAM. After initial plating for four days to allow attachment, cells were subsequently fed 
MGM every two days until becoming fully confluent on Day 7 with a network of elongating 
myotubes. At this point, 5 mm tissue-engineered bone-tendon anchors were pinned onto the cell 
monolayers at a spacing of 2.5 cm, and the medium was switched to muscle differentiation 
medium (MDM). MDM was composed of 35mL M199 (Gibco, cat. no. 11150-059), 11.5mL DMEM, 
3mL FBS, 500µL ABAM, 50µL insulin-transferrin selenium-X (Sigma, cat. no. I1884), and 36.2µL 
50mM ascorbic acid 2-phosphate. After a week on MDM, re-supplied every other day, the 
monolayers delaminated from the plates on Day 14, rolling into cylindrical muscle constructs, 
held at length by the engineered bone anchors (Figure 9).  
Immunocytochemical Analysis 
At specific time points during SMU fabrication, samples were fixed in 20°C methanol for 
10 min and set aside for ICC. Samples were washed for 10 min in 0.1% Triton X-100 (Sigma, cat. 
no. T8787) in DPBS (PBST) and blocked with PBST containing 3% Bovine Serum Albumin (PBST-S; 
Sigma, cat. no. A2153) at room temperature. Samples were then incubated overnight at 4°C with 
primary antibodies diluted in PBST-S. Immunofluorescent staining was performed using the 
following primary antibodies: mouse monoclonal anti-desmin (1:20 dilution; Developmental 
Studies Hybridoma Bank, Iowa City, IA, cat. no. D3), mouse monoclonal anti-Pax7 (1:100 dilution; 
Abcam, Cambridge, MA, cat. no. ab199010), rabbit polyclonal anti-PDGFRα (1:100 dilution; Santa 
Cruz Biotech, Dallas, TX, cat. no. sc-431), biotin conjugated sheep polyclonal anti-BrdU (1:50 
dilution; Abcam, cat. no. ab2284), mouse monoclonal anti-MyoD (1:100 dilution; BD Biosciences, 
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San Jose, CA, cat. no. 554130), rabbit polyclonal anti-fibroblast-specific protein 1 (FSP1; 1:100 
dilution; Abcam cat. no. ab27957), and mouse monoclonal anti-α-actinin (1:200 dilution; Sigma, 
cat. no. A7752). Plates stained with anti-BrdU had previously been incubated for 24 hours with a 
BrdU labelling reagent (Life Technologies, cat. no. 00-0103) in the muscle growth medium. 
Following 3 PBST washes for 5 min each, samples were incubated in 1:500 dilutions of with Alexa 
Fluor anti-mouse, anti-rabbit, or streptavidin secondary antibodies (Life Technologies) for 3 hours 
at room temperature. Following 3 washes in PBST for 15 min each, samples were preserved in 
Prolong Gold with DAPI (Life Technologies, cat. no. P36935) and cover slipped.  
Samples were examined and photographed with a Leica Inverted microscope, and images 
were analyzed using the ImageJ software package (National Institutes of Health, Bethesda, 
MD)141. For ICC analysis, samples from each experimental group were fixed and stained (on Day 
0 for Cytospin; Day 4 for BrdU; and Day 11 for α-actinin). Cells fixed on Day 0 were attached to 
microscope slides via Cytospin at 800 RPM for 8 min. From each sample, ten random areas were 
imaged, and the number of positively stained nuclei in each image was counted.  
Myotube Fusion Index Calculation 
From the α-actinin images, the percentage of myogenic nuclei was first calculated by 
dividing the total number of DAPI-positive nuclei by the number of nuclei associated with an α-
actinin-positive cell. The structural protein α-actinin is often used to identify Z-lines in skeletal 
muscle sarcomeres, but α-actinin is also expressed in the stress fibers of myoblasts prior to 
fusion142-144. To calculate myotube fusion index, α-actinin-positive muscle cells were quantified 
depending on the number of nuclei contained. Specifically, muscle cells were divided into groups 
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with one, two, three, and four or more nuclei, and these values were reported as a percentage 
of the total number of α-actinin-positive nuclei. 
Myotube Size and Density Analysis 
On Day 14 after initial seeding, light micrographs of monolayers were captured. Ten areas 
of approximately 1 mm2 were randomly selected from both the center and periphery of each 60 
mm plate and imaged. Every myotube from these images was then measured in ImageJ to 
determine its diameter and the overall density of the developing myotube network. 
SMU Contractile Measurements 
SMU force production was measured on Day 16 following roll-up into 3D cylindrical form. 
The protocol for measuring contractility of engineered muscle constructs has been described 
previously31,127,145. Briefly, the pin on one end of the SMU was attached to a force transducer 
with a 0-5 mN range and a 0.4 μN resolution (World Precision Instruments, Sarasota, FL, cat. no. 
SI-KG7A). Platinum wire electrodes were placed along either side of the SMU for field stimulation. 
The temperature of the construct was maintained at 37° C, using a heated aluminum platform. 
Twitch contractions were elicited using a single 5 ms pulse at 10, 30, 60 and 90 mA, whereas 
tetanic force was determined using a 1 s train of 5 ms pulses at 90 mA and 10, 20, 40, 60 and 80 
Hz. Data files for each peak twitch force and peak tetanic force trace were recorded and 
subsequently analyzed using LabVIEW 2013 (National Instruments, Austin, TX).  
Statistical Analysis 
Values are presented as mean ± standard error. Measurements of significant differences 
between means were performed using GraphPad Prism 7 software (GraphPad Software, Inc., La 
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Jolla, CA). Means were compared using either a Student’s t-test or one-way ANOVA with Tukey 
post-hoc comparisons. Differences were considered significant at p<0.05. 
 
Results 
 Initial Validation of Microfluidic Satellite Cell Purification 
 The sorting efficiency of the Labyrinth microfluidic device was validated using 
fluorescently labeled primary mouse cells. A combination of Pax7-positive satellite cells 
expressing red tdTomato fluorescence and Achilles tendon fibroblasts labeled with CellTracker 
Green fluorescent dye were separated at several different fluid flow rates. Visualization of the 
fluorescent cells during sorting (Figure 8C) indicated improved separation distances between 
satellite cells and fibroblasts at lower flow rates (1800 µL/min: 148 µm, 2000 µL/min: 135 µm, 
2200 µL/min: 128 µm, 2500 µL/min: 112 µm). Based on these results, a flow rate of 1800 µL/min 
was used for all subsequent sorting runs. Sorting of the fluorescently labeled cell populations was 
repeated, and the separated cells were quantified with a hemocytomer (Table 3A). From these 
results, it is clear the Labyrinth separated the cell populations as intended, significantly enriching 
the satellite cell population in Channel 1 (p = 0.015) and the fibroblast population in Channel 2 (p 
> 0.001) as compared to unsorted controls.  
Isolated Cell Populations Immediately Following Microfluidic Sorting 
The Labyrinth device demonstrated similar sorting efficiency in separating isolated 
primary rat cells (Table 3B). Following isolation and sorting, cells attached to microscope slides 
via Cytospin were immunostained with Pax7 and desmin to characterize myogenic cells and 
PDGFRα to identify fibroblast progenitors.  Analysis of images from the separated cell populations 
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indicated that a purified population of myogenic cells was evident in Channel 1 of the Labyrinth 
device. Specifically, compared to the unsorted muscle dissociation, with a myogenic cell purity of 
39.9 ± 4.0%, Labyrinth-sorted cells were significantly enriched with myogenic cells, approximately 
two-fold, to 75.5 ± 1.6% (p < 0.001). Because of their larger cell size, the fibroblast cells were 
separated into Channels 2, 3, and 4 by the Labyrinth device. In comparison to the unsorted 
dissociation with a fibrogenic cell purity of 45.6 ± 3.1%, channels 2, 3 and 4 demonstrated 
increased fibroblast purities of 57.4 ± 2.7% (p = 0.1091), 60.8 ± 4.9% (p = 0.023), and 78.3 ± 4.5% 
(p < 0.001), respectively.  
 












Pax7+ Purity  
(n = 3) 
33.3 ± 3.4 % 
66.5 ± 6.0 % 
* 
27.2 ± 5.8 % 21.2 ± 11.6 % 0.00 ± 0.00 % 
Fibroblast Purity 
(n = 3) 
43.2 ± 2.6 % 11.9 ± 4.8 % 
70.6 ± 1.3 % 
* 
17.4 ± 3.0 % 0.2 ± 0.1 % 
B) Primary  
Rat Cells 
Myogenic Purity 
(n = 6) 
39.9 ± 4.0 % 
75.5 ± 1.6 % 
* 
27.5 ± 4.2 % 12.0 ± 1.6 % 7.36 ± 1.3 % 
Fibrogenic Purity 
(n = 6) 
45.6 ± 3.1 % 21.9 ± 1.9 % 57.4 ± 2.7 % 
60.8 ± 4.9 % 
* 
78.3 ± 4.5 % 
* 
Table 3. Purity of separated cell populations following sorting. Purity in mouse cells (A) refers to the 
percentage of fluorescent cells (red for Pax7+ satellite cells, green for fibroblasts) among the total cells counted in 
each Labyrinth channel. It is worth noting that very few cells were present in Channel 4, and none of these cells 
were Pax7+. In rat isolates (B), cells were characterized as myogenic if expressing Pax7 or desmin, and fibrogenic 
based on expression of PDGFRα. The difference in sorted mouse and rat populations, evident in Channels 3 and 
4, can be explained by the methods used to label these cells. The mouse cells contained a population of unlabeled 
fibroblasts from enzymatic digestion of the muscle biopsy. It is expected that these unlabeled fibroblasts 
represented a sizeable portion of the mouse cells sorted into Channels 3 and 4. In all tables and figures, values are 




 Effects of Microfluidic Sorting on Cell Proliferation 
 To assess the influence of the microfluidic separation process on cell proliferation, 
Labyrinth sorted cells were seeded and cultured normally. ICC analysis was performed on Day 4 
following seeding to identify proliferating cells expressing BrdU, a synthetic nucleoside analog of 
thymidine. Expression of MyoD and FSP1 was examined simultaneously to identify myogenic cells 
and matrix-secreting fibroblasts, respectively. From BrdU analysis of plates (n = 10), it was clear 
that microfluidic sorting did not have an effect on overall cell proliferation (Figure 10).  
     
In unsorted controls 91.2 ± 1.2% of cells were proliferating, whereas cells sorted into 
Channel 1 of the labyrinth exhibited 91.6 ± 1.0% proliferating cells (p = 0.556).  Co-staining for 
MyoD, however, demonstrated a significant increase (p = 0.004) in proliferating myogenic cells 
 
Figure 10. Myogenic and fibrogenic proliferation of sorted cells. 
Incorporation of BrdU on Day 4 of SMU fabrication was used to identify 
proliferating cells. No difference in overall proliferation was observed 
between unsorted controls (91.2 ± 1.2%) and cells sorted into Channel 1 
(91.6 ± 1.0%, p = 0.556), suggesting sorting did not adversely affect cell 
growth. Immunostaining for MyoD and FSP1 indicated myogenic and 
fibrogenic cells, respectively. Proliferating myogenic cells were 
significantly enriched (p = 0.004) after sorting into Channel 1 (57.1 ± 
3.0%) as compared to unsorted controls (44.3 ± 2.8%). In contrast, FSP1 
staining indicated proliferating fibrogenic cells in unsorted controls, 46.9 
± 1.9%, were significantly decreased to 34.5 ± 1.9% by microfluidic 




sorted into Channel 1 (57.1 ± 3.0%) as compared to unsorted controls (44.3 ± 2.8%). In contrast, 
FSP1 co-staining indicated that the percentage of proliferating fibrogenic cells in unsorted 
controls, 46.9 ± 1.9%, was significantly decreased to 34.5 ± 1.9% by microfluidic sorting (p < 
0.001). It is worth noting that insufficient myogenic cells for seeding and SMU fabrication were 
present in Channels 2, 3, and 4, so only unsorted controls and Channel 1 cells were compared for 
this and subsequent analysis. 
 Myogenic Differentiation and Myotube Fusion Following Microfluidic Sorting 
 Myotube fusion index was measured to assess the ability of sorted cells to form a network 
of myotubes following microfluidic separation. Expression of α-actinin on Day 11 of SMU 
fabrication was used to identify fused myotubes and sarcomeric structure. Myotubes in both 
control and Channel 1 plates exhibited dense networks of longitudinally-aligned myofibrils with 
advanced sarcomeric structure (Figures 11A & B). Quantification of the number of nuclei 
associated with α-actinin-positive cells yielded a myotube fusion index value. From a t-test, the 
overall percentage of nuclei associated with cells expressing α-actinin in unsorted control plates 
(n = 8) of 52.0 ± 2.8% was not significantly different (p = 0.142) from plates seeded with cells 
sorted into Channel 1 57.0 ± 2.1% (Figure 11C). However, the number of fused myotubes with 
four or more nuclei in unsorted control plates, 82.7 ± 3.7%, was significantly increased to 92.3 ± 
2.0% in Channel 1 plates (p < 0.001, Figure 11D). 
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Further analysis of the myotube network was performed on Day 14 of the fabrication 
protocol using light microscopy. The average myotube diameter in unsorted controls (n = 10) was 
16.0 ± 1.3 µm. This value was nearly identical (p = 0.938) to the myotube diameter of 16.2 ± 1.4 
µm in cells sorted into Channel 1 (Figure 12). In contrast, the density of the myotube networks in 
unsorted and sorted samples exhibit a stark difference. Specifically, unsorted control plates 
averaged 18.6 ± 3.3 myotubes/mm2, whereas cells sorted into Channel 1 formed a significantly 
denser, more aligned network (p = 0.004) averaging 33.9 ± 3.7 tubes/mm2. 
 
 
Figure 11. Structural maturation following microfluidic sorting. (A&B) Advanced 
sarcomeric structure within highly-aligned myofibrils, evident from immunostaining for α-
actinin, was observed on Day 11 in both unsorted controls and Channel 1 plates. (C) No 
significant difference was recorded in the total nuclei associated with α-actinin-positive 
muscle cells (p = 0.142). (D) Quantification of myotube fusion index, the percentage of 
muscle cells with either 1, 2, 3, or 4+ nuclei, indicated greater fusion following microfluidic 
sorting. The percentage of fully fused myotubes with 4+ nuclei significantly increased from 
82.7 ± 3.7% in unsorted controls to 92.3 ± 2.0% in Channel 1 (p < 0.001). * Indicates 




   
Force Production in 3D SMUs after Microfluidic Sorting 
 Finally, overall function of engineered SMUs was assessed by contractile force production 
on Day 16, following monolayer delamination and capture in 3D form. As shown in Figure 13, the 
peak isometric tetanic force production in unsorted control SMUs (n = 8) of 71 ± 8 µN was 
significantly increased (p = 0.002) approximately two-fold to 144 ± 17 µN in SMUs fabricated from 
cells sorted into Channel 1 of the Labyrinth microfluidic device. 
 
Figure 12. Effects of microfluidic sorting on myotube growth. Shortly before 
delamination, light microscopy images were captured on Day 14 to assess the size and 
density of myotubes within the developing muscle monolayer. (A&B) Representative images 
of monolayers from unsorted cells and cell sorted into Channel 1. Scale Bar = 500 µm. (C) 
The average myotube diameter was indistinguishable between the two groups: 16.0 ± 1.3 µm 
in controls and 16.2 ± 1.4 µm in Channel 1 (p = 0.938). (D) Channel 1 cells, however, exhibited 
a significantly denser myotube network (p = 0.004), with 33.9 ± 3.7 tubes/mm2 in comparison 




       
Discussion   
Cells separated with microfluidic sorting were analyzed to assess effects on the myogenic 
purity of the isolated population, along with capability for subsequent proliferation, 
differentiation, and function. Immediately following microfluidic sorting, two-fold enrichment of 
the myogenic population was observed in Channel 1 of the Labyrinth device. This enrichment 
was expected based on the design of the Labyrinth device for focusing smaller particles and cells, 
including satellite cells and myogenic progenitors, into Channel 1. In contrast, the fibroblast 
population was enriched in Channels 2, 3, and 4. Again, this result was intended, since the 
Labyrinth was designed to focus the larger fibroblasts into these channels. A minority population 
of fibroblasts was present in Channel 1, however, and a similar population of myogenic cells was 
captured in Channel 2, indicating that microfluidic sorting did not occur with maximal efficiency. 
It is expected that the overlap in the size distributions of satellite cells (8-13 µm34,58) and of 
 
Figure 13. SMU functional development with microfluidic sorting. 
Functional measurement of isometric tetanic force in 3D SMUs on Day 
16 indicated a significant effect of sorting: unsorted control SMU force 
production of 71 ± 8 µN was significantly increased (p = 0.002) 
approximately two-fold to 144 ± 17 µN in Channel 1 SMUs. * Indicates 




fibroblasts (10-22 µm133,134) led to this reduced sorting efficiency. Alternatively, large aggregates 
of undigested extracellular matrix debris were observed in the microfluidic device during sorting 
and in outlet Channels 3 and 4 (data not shown). This debris may have impeded fluidic focusing 
of the different cell populations and reduced the overall sorting efficiency. Nevertheless, the 
majority of satellite cells and fibroblasts were consistently separated as desired by the Labyrinth 
device. 
After microfluidic sorting, cells separated into Channel 1 were not adversely affected by 
the high shear forces imposed during flow through the Labyrinth device. These sorted cells 
exhibited similar overall proliferation to unsorted cells, in addition to improved myogenic 
proliferation and suppression of non-myogenic proliferation. We know that these sorted cells 
were more myogenically pure at seeding from our ICC analysis immediately after microfluidic 
separation, and observation of improved myogenic proliferation confirms this result. Improved 
myogenesis continued as sorted cells differentiated and fused to form a greater number of 
skeletal muscle myotubes. Increased myoblast fusion index was observed in cells sorted into 
Channel 1, resulting in a denser and highly aligned network of myotubes in the differentiation 
phase of SMU formation. Additionally, structural maturation of the muscle monolayers, indicated 
by advanced sarcomeric structure within the highly-aligned myofibrils, was observed in both 
unsorted control and Channel 1 plates. Ultimately, these improvements in myogenic proliferation 
and differentiation translated to greater force production in SMUs fabricated from Channel 1 
cells. In conclusion, microfluidic sorting efficiently separated satellite cells and fibroblasts while 





 Microfluidic sorting, as demonstrated in this study, offers an alternative approach to 
purification of satellite cells enzymatically digested from a muscle biopsy. The most comparable 
approach, pre-plating to remove rapidly adhering non-myogenic cells, can achieve greater than 
80% myogenic purity40. The primary drawbacks to pre-plating, however, are the length of time 
required (5 days) and the potential for decreased cell yields. Recently, purification of isolated 
satellite cells through FACS has gained popularity due to its ability to rapidly sort Pax7+ satellite 
cells with greater than 90% purity60,146. With FACS, labeling with exogenous dyes is required, and 
incubation with these antibodies decreases throughput. Microfluidic sorting has the potential to 
fill a niche distinct from these established methods. Although the myogenic purity of cells 
separated with the Labyrinth devices was slightly lower at 75%, the sorting process was label-
free and required approximately 5 minutes. For tissue engineers, this high-throughput and label-








Dexamethasone Supplementation to Enhance Myogenic Differentiation in 
Engineered SMUs 
The text and figures in this chapter were originally published with the following citation:  
Syverud BC, VanDusen KW, and Larkin LM. “Effects of dexamethasone on satellite cells and tissue 
engineered skeletal muscle units.” Tissue Eng Pt A 22(5-6): 480 (2016). Excerpts from this article 
have been included with permission from the publisher, Mary Ann Liebert, Inc. 
Introduction 
Potential applications for engineered skeletal muscle include implantation as a graft 
material for repair of traumatic damage30,69, recapitulation of native development and 
regeneration for detailed physiological study or pharmaceutical testing27, and use as 
biomechanical actuators70,71. In each case, recreating the complex function and structure of 
skeletal muscle in vivo is a challenging, but essential, consideration. Engineered tissues to date, 
however, have been characterized by a neonatal phenotype in terms of force production and 
structural maturity26,29. Following sufficient recovery time, engineered skeletal muscles 
implanted into an in vivo regenerative environment have advanced towards the adult 
phenotype24,72, and several studies have attempted to utilize key chemical and mechanical stimuli 
to improve the maturity of these engineered muscles in vitro65,73.  
56 
 
 Tissue engineers have used the influence of such growth factors on myogenesis to direct 
techniques for engineering skeletal muscle. Current tissue engineering techniques utilize scaffold 
materials, ranging from acellularized tissues95,96 to collagen and fibrin hydrogels26,27,97, or opt for 
a scaffold-free approach28,29,72 to support development of extracellular matrix (ECM) for 
subsequent muscle tissue. The ultimate success of these approaches depends on the in vitro 
culture of isolated primary muscle precursor cells. A common technique in cultivation of these 
myogenic cells begins with an initial proliferation phase, allowing cells to expand sufficiently, 
followed by induction of differentiation and fusion into myotubes98. Use of media with high serum 
content is generally accepted to promote the initial proliferation phase while delaying the onset 
of differentiation, potentially due to the presence of a variety of growth factors38. Drastic 
reduction in media serum content subsequently triggers satellite cell differentiation, possibly due 
to the removal of essential mitogenic components. Because of variations in the activity and 
concentration of growth factors between lots of commercially available serum, as well as the 
consequent variability in satellite cell induction and proliferation, an optimum serum formulation 
and the identity of these mitogenic components has yet to be fully defined44. By understanding 
the essential growth factors and supplementing media with the appropriate doses, tissue 
engineers can maximize the myogenic potential of satellite cells when engineering skeletal 
muscle. 
The synthetic glucocorticoid dexamethasone (DEX) has previously been studied due to its 
profound effects on muscle in vivo and on satellite cell cultures in vitro, but its application in 
skeletal muscle tissue engineering has yet to be evaluated. In a clinical setting, DEX is typically 
used for its anti-inflammatory or immunosuppressant activity to treat several rheumatologic and 
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skin diseases, because it is 25 times more potent than endogenous cortisol147. In skeletal muscle 
specifically, exogenously delivered DEX has a variety of effects depending on the timing and 
dosage of the administration. DEX induces atrophy in adult human skeletal muscle when supplied 
orally in 4 mg doses, approximately 10 times greater than endogenous cortisol levels148,149. This 
atrophic effect has been linked to up-regulation of the myostatin promoter and inhibition of IGF-
1 expression148,150. In contrast, the administration of 5 to 25nM DEX has improved myogenesis in 
vitro by enhancing differentiation and myotube fusion of myogenic murine cells, potentially 
through its induction of dysferlin, a calcium-binding transmembrane protein thought to play a key 
role in both myogenesis and membrane repair151. Similar studies have demonstrated that DEX 
can inhibit protein synthesis and myoblast proliferation in vitro 152, however, reinforcing the need 
for careful timing of addition to culture.  
Recent research from our lab has focused on optimizing and testing Skeletal Muscle Units 
(SMUs), cylindrical tissue constructs featuring muscle fabricated from monolayers of primary 
fibroblasts and contractile myotubes9. The papers referenced above regarding DEX activity in vitro 
describe its effects on the immortal C2C12 mouse myoblast cell line in two-dimensional culture, 
rather than the primary cell population and functional three-dimensional constructs used in our 
SMU experiments. We hypothesized that exposing the heterogeneous pool of satellite cells and 
fibroblasts used for SMU fabrication to different doses of DEX at several time points may yield an 
optimal combination for improving myogenesis and ultimately maximizing in vitro development 
of our engineered skeletal muscle.  Thus, the purpose of this study was to examine the potential 






Tissue engineering studies were conducted using soleus muscles and bone marrow from 
145-155g female Fischer 344 rats, obtained from Charles River Laboratories Inc. (Wilmington, MA, 
USA) and Harlan Laboratories (Haslett, MI, USA). All animals were acclimated to colony conditions 
for one week prior to any procedure. Animals were fed Purina Rodent Chow 5001 and water ad 
libitum.  All surgical procedures were performed in an aseptic environment, with animals in a 
deep plane of anesthesia induced by intraperitoneal injections of sodium pentobarbital (65 
mg/kg). Supplemental doses of pentobarbital were administered as required to maintain an 
adequate depth of anesthesia. All animal care and animal surgery procedures were in accordance 
with The Guide for Care and Use of Laboratory Animals137, and the protocol was approved by the 
University Committee for the Use and Care of Animals. 
SMU formation and Dexamethasone addition 
  SMUs were fabricated in individual coated 60 mm polystyrene plates (BD Falcon, Franklin 
Lakes, NJ, USA), and ICC was performed on 35 mm plates as described previously29,72,127. Briefly, 
a substrate of Sylgard (type 184 silicon elastomer; Dow Chemical Corp., Midland, MI) was initially 
cured onto each plate, followed by coating with laminin (Natural Mouse Laminin, cat. No. 23017-
015; Gibco BRL, Carlsbad, CA) at 1mg/cm2. The cell isolation mixture was plated in muscle growth 
medium (MGM) at a density of 600,000 cells per 60 mm plate and 150,000 cells per 35 mm plate. 
MGM contained 30mL F-12 Kaighn’s Modification Nutrient Mixture (cat. No. 21127-022; Gibco 
BRL), 12.5mL Dulbecco’s modified Eagle’s medium (DMEM; cat. No. 11995- 065; Gibco BRL), 
7.5mL fetal bovine serum (FBS; cat. No. 10437-028; Gibco BRL), 2.4 ng/mL basic fibroblast growth 
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factor (bFGF; cat. No. 100-18B; Peprotech, Rocky Hill, NJ), and 0.5mL antibiotic-anti-mycotic 
(ABAM; cat. No. 15240- 062; Gibco BRL).  
After the initial plating, cells were left undisturbed for four days and subsequently fed 
MGM every two days until becoming fully confluent with elongating myotubes forming a network 
across the base of the plate. Next, 5 mm tissue-engineered bone-tendon anchors were pinned 
onto the cell monolayers 2.5 cm apart, and the medium was switched to muscle differentiation 
medium (MDM). MDM was composed of 35mL M199 (cat. No. 11150-059; Gibco BRL), 11.5mL 
DMEM, 3mL FBS, 50µL insulin-transferrin selenium-X (cat. No. I1884; Sigma-Aldrich, St. Louis, 
MO), 0.5mL ABAM, and 36.2µL 50mM ascorbic acid 2-phosphate. After approximately a week on 
MDM, re-supplied every other day, the monolayers delaminated from the plates, rolling into 
cylindrical muscle constructs, held at length by the engineered bone anchors. During this SMU 
formation process, described in Figure 14, DEX was added to the medium beginning at three 
different time points: initial plating (Day 0), six days after initial plating (Day 6), and two days after 
the switch to MDM (Day 9). These three time points were chosen to evaluate the efficacy of DEX 
in controlling isolated cell proliferation, differentiation, and maturation of the delaminating 
monolayer and subsequent 3D SMU, respectively. After the first addition, supplemental doses of 
DEX were added with each medium change. Three experimental doses were supplied (5nM, 
10nM, and 25nM), with untreated plates as controls.  
SMU contractile measurements 
Contractile properties of SMUs (n=6) from each experimental group were measured 
following roll-up into cylindrical form. The protocol for measuring contractility of engineered 
muscle constructs has been described in the previous chapter145,153. To reiterate, the pin on one 
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end of the SMU was raised from the Sylgard and attached to a force transducer. Platinum wire 
electrodes were placed along either side of the SMU for field stimulation. The temperature of the 
construct was maintained at 37° C, using a heated aluminum platform. Passive force was 
measured as the average baseline force produced prior to the onset of stimulation. Twitch 
contractions were elicited using a single 5 ms pulse at 10, 30, 60 and 90 mA, whereas tetanic force 
was determined using a 1 s train of 5 ms pulses at 90 mA and 10, 20, 40, 60 and 80 Hz. Data files 
for each peak twitch force and peak tetanic force trace were recorded and subsequently analyzed 
using LabVIEW 2013.  
 
 
Figure 14. Experimental timeline with dexamethasone timings and dosages. Addition of dexamethasone was 
initiated at three time points: on Day 0 to study effects on proliferation, on Day 6 to study effects on late proliferation 
and differentiation, and on Day 9 to study effects on structural maturation. During this SMU fabrication process, 
subsets of the developing plates were analyzed for expression of BrdU, MyoD, Fibroblast-specific protein 1 (FSP1), 
myogenin, and α-actinin as listed above. Additionally, myotube fusion and myotube size and density were 
measured in the developing muscle monolayers. Finally, the 3D SMUs were assessed for force production in 
response to electrical stimulation and for strucutral development with TEM. MGM stands for Muscle Growth 




 Immunocytochemical Analysis 
During SMU fabrication, a subset of the plates from each experimental group was fixed in 
20°C methanol for 10 min and set aside for immunocytochemistry (ICC). The plates were 
submerged for 15 min in 0.1% Triton X-100 (Sigma, St. Louis, MO, USA, cat. no. T8787) in DPBS 
(PBST) and blocked with PBST containing 3% Bovine Serum Albumin (PBST-S; Sigma, cat. no. 
A2153) at room temperature. The sections were then incubated overnight at 40C with the primary 
antibodies diluted in PBST-S. Immunofluorescent staining with specific antibodies was performed 
to detect the presence of BrdU (biotin conjugated sheep polyclonal antibody; Abcam, Cambridge, 
MA, USA, cat. no. ab2284), MyoD (mouse monoclonal antibody 1:100 dilution; BD Biosciences, 
San Jose, CA, USA, cat. no. 554130), FSP1 (rabbit polyclonal antibody 1:100 dilution; Abcam, cat. 
no. ab27957), myogenin (rabbit polyclonal antibody 1:50 dilution; Santa Cruz Biotechnology, 
Dallas, TX, USA, cat. no. sc-576), desmin (mouse monoclonal antibody 1:20 dilution; 
Developmental Studies Hybridoma Bank, Iowa City, IA, USA, cat. no. D3), and α-actinin (mouse 
monoclonal antibody 1:200 dilution; Sigma, cat. no. A7752). Plates stained with antibodies for 
BrdU had previously been incubated for 24 hours with a BrdU labelling reagent (Life Technologies, 
cat. no. 00-0103) in the culture media. Following three washes in PBST, samples were incubated 
in 1:500 dilutions of with Alexa Fluor anti-mouse, anti-rabbit, or streptavidin secondary 
antibodies (Life Technologies) for three hours at room temperature. Following three washes in 
PBST, samples were preserved in Prolong Gold with DAPI (Life Technologies, cat. no. P36935) and 
cover slipped. 
Samples were examined and photographed with a Leica Inverted microscope, and images 
were analyzed using the ImageJ software package. For ICC analysis, plates (n=5) from each 
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experimental group were fixed and stained (on Day 4 for BrdU, MyoD, and FSP1; Day 7 for 
myogenin; and Day 11 for desmin). From each plate, ten areas were randomly selected and 
imaged, and the number of positively stained nuclei in each image was counted. To calculate 
myotube fusion index from the desmin images, the number of nuclei associated with a desmin-
positive myotube was divided by the total number of nuclei.  
Myotube Size and Density Analysis 
On day 14 after initial plating of satellite cells, light micrographs of the developing 
monolayers in each experimental group were captured and analyzed. Specifically, five areas from 
each 60 mm plate (n=8) were randomly selected and imaged. Every myotube from these images 
was then measured in ImageJ to determine its size and the overall density of the myotube 
network. 
Transmission Electron Microscopy Analysis 
Following measures of mechanical function, SMUs were fixed overnight at room 
temperature in 0.1M phosphate buffer (Fisher Scientific, Pittsburgh, PA, USA, cat. no. S369-500) 
containing 2.5% glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA, USA, cat no. 16210), 
post fixed at 4°C for one hour in 0.1M phosphate buffer containing 1% osmium tetroxide (Electron 
Microscopy Sciences, cat no. 19150), and polymerized in Embed 812 resin (Electron Microscopy 
Sciences, cat. no. 14900) at 60°C for 24 hours. Ultra-thin 70nm sections were then cut and stained 
with uranyl acetate (Electron Microscopy Sciences, cat. no. 22400) and lead citrate (Electron 
Microscopy Sciences, cat. nos. 17900 and 21140) and imaged using a JEOL JEM-1400Plus 




Values are presented as mean ± SE. Measurements of significant differences between 
means were performed using GraphPad software. Means were compared using either one-way 
or two-way ANOVA tests with Tukey post-hoc comparisons. Differences were considered 
significant at p<0.05. 
 
Results 
Effects of Dexamethasone on Proliferation of Satellite Cells 
To assess the influence of DEX on the induction and proliferation of isolated myogenic 
satellite cells, DEX was added at the time of plating (Day 0). ICC analysis of cells expressing BrdU, 
a synthetic nucleoside analog of thymine, was used on Day 4 to identify proliferating cells154, and 
expression of MyoD and Fibroblast-specific protein 1 (FSP1) was examined simultaneously to 
identify myogenic cells and matrix-secreting fibroblasts, respectively (Figure 15). From the 
analysis of BrdU and MyoD co-staining, a dose dependent response to DEX treatment was 
evident, with the density of proliferating myogenic nuclei increasing with increasing DEX 
concentration. Following addition of 10nM and 25nM DEX, a statistically significant increase in 
MyoD+ cell proliferation relative to No DEX controls was observed (p = 0.012 and 0.003, 
respectively). Addition of 5nM DEX exhibited no difference from controls and resulted in 
significantly fewer proliferating MyoD+ cells than the 10nM and 25nM DEX doses (p = 0.037 and 
0.009, respectively). Similarly, ICC analysis for both BrdU and FSP1 showed that the administration 
of DEX on Day 0 led to a decrease in the number of proliferating FSP1+ cells. This decrease in 
FSP1+ cells was significant following 10nM and 25nM DEX addition, relative to untreated controls 
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(p = 0.002 and 0.004, respectively). Administration of 5nM DEX indicated no difference in FSP1+ 
cells from No DEX controls. In comparison to the 10nM and 25nM concentrations, however, 5nM 
DEX yielded significantly decreased proliferation of FSP1+ cells (p = 0.004 and 0.005, respectively).  
Thus, the results for MyoD and FSP1 expression in proliferating cells demonstrate that the 
influence of 10nM and 25nM DEX on early growth of heterogeneous muscle isolates was two-
fold: improved proliferation of cells in the myogenic lineage and decreased proliferation of non-
myogenic fibroblasts. 
 
Dexamethasone Induction of Muscle Cell Differentiation and Myotube Fusion 
ICC analysis of myogenin expression was used as an indicator of myoblast differentiation 
into myotubes on Day 7 of the experiment155. A dose-dependent increase in myogenin-positive 
 
Figure 15. Myogenic and fibroblast cell proliferation following dexamethasone addition. (A) With DEX 
addition on the day of initial seeding (D0), the percentage of proliferating cells expressing MyoD followed an 
increasing trend with increasing DEX concentration, as indicated by BrdU and MyoD co-staining on Day 4. 
A statistically significant increase in proliferation (p = 0.012 for 10nM, p = 0.003 for 25nM) was observed 
when comparing the higher concentrations of DEX (10nM and 25nM) to untreated controls (No DEX).  (B) 
ICC analysis for BrdU and FSP1 on Day 4 showed a decrease in the percentage of proliferating cells 
expressing FSP1+ following DEX addition. In response to administration of 10nM and 25nM DEX, the number 
of proliferating cells expressing FSP1 significantly decreased relative to No DEX controls (p = 0.002 and 
0.004, respectively). Error bars indicate mean ± standard error. * Indicates statistical difference from control, 




cell density was observed in response to DEX treatment, independent of the timing of its addition 
(Figure 16A). Groups receiving 5nM DEX showed no difference from No DEX controls, whereas 
10nM addition significantly increased the number cells expressing myogenin (p = 0.001), and 
25nM DEX led to even greater increases (p < 0.001). Ultimately, treatment with 25nM DEX 
beginning on Day 6 yielded the highest density of myogenin+ cells, approximately 2.8 times 
greater than untreated controls.  
 
Myotube fusion index was measured to assess the ability of myoblasts to terminally 
differentiate and form a network of myotubes in the presence of DEX. Expression of desmin, a 
protein specific to muscle cells and a key subunit in intermediate filaments38,156, identified fused 
myotubes, and subsequent analysis of the percentage of nuclei associated with a myotube 
 
Figure 16. DEX effects on myogenic differentiation. (A) ICC analysis for myogenin expression on Day 7 
indicated differentiation of myoblasts into myotubes. From two-way ANOVA, a dose-dependent increase in 
myogenin-positive cell density was observed in response to DEX treatment (p < 0.001), independent of the timing 
of addition. (B) Myotube fusion index, calculated from desmin and DAPI staining on Day 11, quantified the number 
of nuclei associated with a myotube as a percentage of total nuclei. Two-way ANOVA indicated a significant effect 
of both DEX dose and timing (p < 0.001 for both). When averaged across the three timing groups, all three DEX 
concentrations yielded significantly increased myotube fusion relative to No DEX controls (p = 0.002 for 5nM, p > 
0.001 for 10nM and 25nM). Similarly, fusion index increased significantly with DEX addition on Day 0 and Day 6 (p 
= 0.015 and 0.008, respectively). Error bars indicate mean ± standard error. * Indicates statistical difference from 
No DEX controls, # from 5nM in the same DEX timing group, ♦ from 10nM in the same timing group, † from 25nM 
in the same timing group, (a) from Day 0 at the same DEX dose, (b) from Day 6 at the same DEX dose, and (c) 




yielded a myotube fusion index value. Two-way ANOVA indicated that both the dose and timing 
of DEX addition significantly affected myotube fusion (Figure 16B). Compared to untreated 
controls, all three experimental concentrations significantly increased myotube fusion (p = 0.002 
for 5nM, p > 0.001 for 10nM and 25nM). The effect of time indicates that the early addition of 
DEX at cell seeding (Day 0) or towards the end of the proliferative stage (Day 6) significantly 
increased myotube fusion (p = 0.015 and 0.008, respectively), whereas plates treated with DEX 
during the differentiation stage (Day 9) exhibited no difference from controls. Although no 
difference in myotube fusion was observed between the 5nM, 10nM, and 25nM concentrations 
when averaged across the three timing groups, focus on the Day 6 time point alone revealed a 
dose-dependent trend, with fusion index increasing with each DEX concentration. This trend 
included a statistically significant difference between the Day 6 5nM and 25nM DEX 
concentrations (p = 0.007). Across all experimental groups, addition of 25nM DEX on Day 6 yielded 
the highest myotube fusion index at 69%, a 250% increase over the No DEX controls. The 
combined results for myogenin expression and myotube fusion demonstrate that DEX addition 
increased myogenic differentiation and myotube fusion, with the addition of the highest 
experimental dose, 25nM, on Day 6 producing the greatest increases. 
Further analysis of myotube size and number was performed on Day 14, immediately prior 
to monolayer delamination. The dose and timing of DEX addition were observed to have 
significant effects on myotube diameter (Figure 17E). In response to the experimental DEX 
concentrations, a significant dose-dependent increase in myotube diameter was observed, 
resulting in myotubes 1.2, 1.3, and 1.4 times larger than No DEX controls following addition of 
5nM, 10nM, and 25nM DEX, respectively (p = 0.001 for 5nM, p < 0.001 for 10nM and 25nM). 
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Additionally, in plates receiving DEX at the two early time points, Day 0 and Day 6, myotube 
diameters increased significantly relative to untreated controls (p < 0.001 for both days). Plates 
subsequently treated with DEX on Day 9 showed no difference in myotube diameter from 
controls. Day 6 addition of 10nM and 25nM DEX produced the largest myotubes, with average 
diameters of 14.8 and 16.1 µm, respectively. Myotube diameters for both doses were significantly 
greater than control myotubes, with an average diameter of 9.8 µm (p < 0.001 for both doses).  
 
 
Figure 17. DEX effects on myotube growth. Monolayers were observed just prior to delamination on Day 14. 
Representative images are shown above for (A) No DEX, (B) Day 6 5nM, (C) Day 6 10nM, and (D) Day 6 25nM. 
Images from the Day 6 timing group were chosen because this time point demonstrated the significant effects of 
DEX addition detailed below. The black arrowheads in (B) & (D) indicate blebbing of myotubes. All images were 
analyzed for (E) myotube diameter and (F) myotube density. The effects of DEX dose and timing on myotube size 
were both evident from two-way ANOVA (p < 0.001 for both). Post-hoc analysis demonstrated significant increases 
in myotube diamter in response to all three DEX concentrations (p = 0.001 for 5nM, p < 0.001 for 10nM and 25nM). 
Similarly, Day 0 and Day 6 DEX addition led to significantly increased myotube diameters relative to untreated 
controls (p < 0.001 for both days). When examining myotube density, the timing of DEX addition had a significant 
effect (p = 0.004). Specifically, the number of myotubes increased significantly with DEX addition on Day 6 in 
comparison to No DEX controls (p = 0.008) , but Day 0 and Day 9 addition resulted in no significant difference. 
Error bars indicate mean ± standard error. * Indicates statistical difference from No DEX controls, (a) from Day 0 




The effects of the timing of DEX addition on the overall density of the myotube network 
were also evident. Administration of DEX on Day 6 improved myotube density significantly (p = 
0.008), while addition of DEX on Day 0 and Day 9 exhibited no significant differences from 
untreated controls. Similarly, no significant differences were observed when examining the 
influence of the three DEX doses on myotube density. Together, the myotube size and density 
data indicate that the addition of DEX on Day 6 leads to a more robust network of larger 
myotubes, which may be preferable for engineering skeletal muscle. 
Structural and Functional Maturation of 3D SMUs with Dexamethasone Addition  
The influence of DEX on the overall structure and function of engineered SMUs was also 
observed during delamination and in the final 3-D form. Immunocytochemical analysis of α-
actinin (Figures 18A & B) demonstrated improved maturation of myotubes in the delaminating 
monolayer following addition of all three DEX concentrations. Plates receiving DEX on Day 0 and 
Day 6 exhibited advanced sarcomeric structure within highly aligned myofibrils in the confluent 
monolayers. This development of sarcomeric structure was not observed in control muscle 
cultures or plates receiving DEX during the differentiation stage on Day 9. Similarly, administration 
of DEX led to improved structural maturation in the fully formed 3D SMUs.  Electron micrographs 
of a SMU receiving 10nM DEX on Day 6 exhibited a denser network of aligned collagen fibers at 
the junctions of each myofiber than the No DEX SMU (Figures 18C & D). Furthermore, following 
10nM DEX administration on Day 6, the resulting SMU demonstrated development of aligned 
myofilaments and maturing Z-lines, similar to the organization of parallel sarcomeres in adult 
skeletal muscle (Figures 18E & F). Aligned myofilaments were evident in untreated control SMUs, 
but few developing sarcomeric structures were observed.      
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This improved structural maturation translated to increased function, as assessed by 
contractile force production in the 3-D SMUs. The maximum isometric tetanic forces produced by 
 
Figure 18. SMU structural maturation with DEX addition. Representative images of 
muscle monolayers (A) without DEX and (B) following DEX addition (Day 0 10nM). 
These images show α-actinin in muscle monolayers 10 days post-seeding. Formation 
of advanced sarcomeric structure and aligned myofibrils was evident in plates receiving 
DEX on either Day 0 or Day 6 in all three experimental concentrations. Transmission 
electron micrographs of longitudinal sections of SMUs following formation of a 3-D 
construct, (C & E) without DEX administration and (D & F) following Day 6 addition of 
10nM DEX, corroborate the positive effects of DEX on structural maturation during SMU 
fabrication. Both No DEX and D6 10nM DEX images show developing ECM at myofiber 
junctions, but greatly increased density and alignment of collagen fibers is evident 
following DEX addition. Similarly, both SMUs contain myofibers with highly aligned 
myofilaments, indicated by asterisks in (C & D). However, the formation of organized Z-
lines indicative of developing sarcomeric structure was observed to a much greater 




engineered SMUs are displayed in Figure 19A, and two-way ANOVA indicated both DEX timing 
and dose significantly affected SMU function.  
     
 
Figure 19. SMU functional maturation with DEX addition. (A) Isometric tetanic force 
production in 3D SMUs indicated a significant effect of both DEX dose and timing (p < 0.001 
for dose, p = 0.004 for timing). Addition of 10nM DEX was optimal for SMU fabrication, 
producing a significant, five-fold increase relative to untreated controls (p = 0.004). 
Additionally, Day 0 and Day 6 administration of DEX both led to a significant, two-fold 
increase in force production (p = 0.016 for Day 0, p = 0.018 for Day 6), whereas Day 9 DEX 
addition yielded a 20% decrease compared to No DEX controls. (B) Examination of passive 
force generation also showed a significant effect of DEX timing and dose (p = 0.004 for 
timing, p < 0.001 for dose). Further analysis indicated that DEX treatment led to significant 
decreases compared to No DEX controls regardless of DEX timing or concentration (p < 
0.001 for Days 0 and 6, p = 0.006 for Day 9, p < 0.001 for 5nM, p = 0.003 for 10nM, p = 
0.002 for 25nM). Error bars indicate mean ± standard error.  * Indicates statistical difference 
from No DEX controls, # from 5nM in the same DEX timing group, ♦ from 10nM in the same 
DEX timing group, † from 25nM in the same DEX timing group, (a) from Day 0 at the same 




When averaging the values across all experimental concentrations to study timing effects, 
administration of DEX on Day 0 and Day 6 both led to a significant, two-fold increase in force 
production (p = 0.016 for Day 0, p = 0.018 for Day 6). Addition of DEX on Day 9 led to a 20% 
decrease in force production compared to No DEX controls. Surprisingly, however, when 
examining the effects of DEX dosage, only addition of 10nM DEX produced a significant 
improvement in function, represented by a five-fold increase in isometric force production 
relative to No DEX controls (p = 0.004). SMUs receiving 5nM DEX showed no increase relative to 
control SMUs, whereas addition of 25nM DEX significantly decreased force production (p = 
0.024). Overall, optimal force production was observed in SMUs receiving 10nM DEX on Day 0 
and Day 6, with average isometric tetanic forces of 257 and 254 µN, respectively.  
Additionally, administration of DEX may have affected the development and maintenance 
of passive tension in the maturing muscle monolayers, and eventually in the SMUs fabricated 
from the monolayers. This passive tension effect was quantitatively observed in the timing of 
delamination of the developing monolayers. Rather than rolling up on Day 14 as is typical in our 
SMU fabrication protocol, plates treated with DEX remained in monolayer form approximately 
20% longer, regardless of the dosage administered. Plates receiving DEX rolled up, on average, on 
day 17, and manual manipulation was occasionally necessary to assist this process. Following 
delamination, passive tension development in the newly formed SMUs was measured during 
assessment of contractile force production 24 hours post roll-up. Two-way ANOVA indicated a 
significant effect of both DEX timing and dose on passive tension (Figure 19B). Further analysis 
showed that addition of DEX addition significantly decreased passive tension in fabricated SMUs 
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(p < 0.001 for Days 0 and 6, p = 0.006 for Day 9, p < 0.001 for 5nM, p = 0.003 for 10nM, and p = 
0.002 for 25nM), regardless of the timing or dose of DEX administration. 
 
Discussion 
 The overall effects of DEX during the SMU fabrication process can be divided into distinct 
proliferation, differentiation, and maturation phases. The addition of DEX prior to myocyte 
differentiation led to improved myogenic proliferation and suppression of non-myogenic 
proliferation, indicated by increased MyoD+ cell density and decreased FSP1+ cell density. In 
addition, administration of 10nM and 25nM DEX at the beginning of proliferation (Day 0) or one 
day prior to the transition from proliferation to differentiation (Day 6) yielded increased myoblast 
fusion, resulting in a dense network of larger myotubes in the subsequent differentiation phase. 
Similarly, addition of DEX during the proliferative stage on either Day 0 or Day 6 resulted in the 
greatest structural maturation of the delaminating monolayers and the resulting fully formed 3D 
SMUs, characterized by the presence of advanced sarcomeric structure within highly aligned 
myofibrils. Ultimately, administration of 10nM DEX during proliferation on either Day 0 or Day 6 
yielded optimal force production in fabricated SMUs.  
 Although administration of 25nM DEX improved myogenic proliferation and 
differentiation, force production in these SMUs actually decreased compared to No DEX controls. 
Several factors potentially explain the ultimate decrease in the contractile function associated 
with addition of 25nM DEX. As described above, supplementation with DEX led to decreased non-
myogenic proliferation and increased myogenesis, concomitant with decreased passive tension. 
Extracellular matrix is essential to SMU fabrication, both for generation of the passive tension 
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promoting delamination and for structural support of the contractile components of the SMU. 
DEX addition may have promoted myogenic differentiation and down-regulated functional 
extracellular matrix formation. Although TEM images indicated increased collagen deposition and 
alignment following DEX treatment (Figures 18C & D), this collagen content did not translate to a 
more robust extracellular matrix, as evident from the decrease in passive tension values. Since 
plates receiving 25nM DEX exhibited the largest myotubes in the highest density, additional ECM 
would be required to support these robust muscle networks, and it is possible that the ECM 
present in the 25nM plates was insufficient to transmit force along the SMUs. Another potential 
explanation was the formation of blebs on the periphery of several myotubes accompanying 
myoblast fusion. This blebbing, seen in the light microscopy images in Figure 17, typically began 
shortly after the switch from M-GM to M-DM on Day 7 and became more pronounced during 
differentiation. Upon gross examination, these blebs were increasingly prevalent at the 25nM 
DEX dosage. Blebbing has been identified as a potential biomarker of cell injury that can occur in 
myotubes in response to toxic agents or hypotonic osmotic shock157. Based on the current 
understanding of the action of DEX in vivo148,150, namely acting as a potential agent for the 
induction of skeletal muscle atrophy, it may be possible to draw a connection between DEX 
addition and myotube membrane damage and blebbing. Further analysis is necessary to 
determine whether membrane blebbing, an inhibition of ECM formation, or some additional 
unexpected cause, resulted in the decrease in force production accompanying 25nM DEX 





 This experiment demonstrates that addition of DEX to isolated muscle satellite cells in 
culture can improve functional and structural characteristics of our tissue-engineered skeletal 
muscle when administered at optimal doses and timings. Addition of DEX prior to induction of 
differentiation improved myogenic proliferation of muscle satellite cells, which subsequently led 
to increased myogenic differentiation and myotube fusion. The benefits of the administration of 
DEX during proliferation were further evident during the SMU maturation phase, as characterized 
by formation of advanced sarcomeric structure and increased contractile function observed in 
the fully formed 3-D SMU. The most promising improvements in SMU function were achieved 
with the addition of 10nM DEX on either Day 0 or Day 6. In addition to increased myogenic 
differentiation and myotube fusion, SMUs exposed to this concentration exhibited advanced 
structural development of sarcomeric structure and a five-fold increase in force production. Thus, 
the utilization of dexamethasone in our existing tissue-engineering model presents a blueprint 











The growing deficit in suitable tissues for patients awaiting organ transplants 
demonstrates the clinical need for engineered tissues as alternative graft sources158,159. Although 
government funding for tissue engineering and regenerative medicine reached $2 billion in 2009, 
only a fraction of potential tissue-engineered products has obtained clinical approval160,161. A 
major obstacle is a lack of non-invasive methods for in vitro validation of construct robustness 
prior to implantation. A reliable, rapid method to assess construct viability is needed that avoids 
destroying or compromising the cell-based device162,163 and yields parameters employable as 
release criteria. Unfortunately, current methods to evaluate engineered tissue viability and 
structural integrity prior to implantation have significant drawbacks, including being invasive, 
destructive, or non-sterile164-166. 
To meet the need for a rigorous, quantitative methodology for evaluating engineered 
tissues in a non-destructive manner, multiphoton microscopy is a promising novel technology. In 
comparison to the gold standards of histology and immunohistochemistry (IHC), multiphoton 
microscopy presents several beneficial aspects163,167. Whereas the combination of histology and 
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IHC can provide spatial information about cells and matrix proteins in a quantitative manner that 
has been accepted by regulatory scientists, multiphoton microscopy adds the ability to acquire 
the same information in real-time without irrevocably damaging the engineered tissue. 
Multiphoton microscopy is a form of non-linear microscopy utilizing laser scanning in an 
extremely thin focal plane. It differs from conventional techniques, such as light microscopy or 
confocal microscopy, by localizing sample excitation to the focal plane alone as multiple photons 
of approximately equal energy are focused onto approximately the same molecular 
component166,168. As a result, multiphoton microscopy is beneficial as a means of imaging in 
thicker tissues, producing minimal photodamage or photobleaching, and avoiding the use of 
labelling reagents. Using such a technology, imaging up to 500 µm into a sample with spatial 
resolution on the order of 1 μm becomes possible166. 
Optical molecular imaging (OMI) techniques utilizing multiphoton microscopy have been 
demonstrated in native skeletal muscle166,169,170 and in select engineered tissues167,168,171, but 
they have not been applied to engineered musculoskeletal tissues. In particular, the following 
OMI approaches have been identified: 1) excitation of endogenous nicotinamide adenine 
dinucleotide (NADH) and flavin adenine dinucleotide (FAD) fluorescence to evaluate metabolic 
activity, and 2) second harmonic generation (SHG) imaging of myosin in skeletal muscle 
sarcomeres and of collagen in the extracellular matrix to assess structural composition. We 
sought to demonstrate the applicability of these OMI approaches to non-invasively evaluate the 
structure and metabolic activity in our tissue-engineered skeletal muscle. 
 For studying metabolic activity, multiphoton excitation fluorescence targeting NADH and 
FAD was monitored. These two mitochondrial coenzymes are necessary for cell metabolism and 
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oxygen consumption and can act as endogenous cellular fluorophores. The reduced and oxidized 
states of these coenzymes naturally fluoresce in response to multiphoton excitation166,167,172,173. 
Captured images of intracellular concentrations of NADH and FAD in engineered tissues can be 
used to characterize size, morphology, and cellular organization174-176. In addition, NADH and FAD 
signals can be used to calculate a redox ratio (RR) metric, calculated as [FAD] / [NADH] + [FAD]167, 
as an indication of metabolic activity. Intensity ratios like the RR metric measure metabolic 
variations with increased sensitivity by reducing intensity-based artifacts, including signal 
variations due to optical loss, which may be difficult to quantify or control in tissues. Previous 
work with engineered oral mucosa fabricated from primary human cells demonstrated the ability 
of this OMI method to detect significantly different RR values in metabolically stressed constructs 
as compared to controls167. Similar nonlinear OMI and quantitative analytic methods were 
applied in the current study to non-invasively assess the viability of engineered skeletal muscle 
constructs. In both our previous and current studies, label-free OMI of local tissue structure and 
biochemistry characterized morphologic and functional differences between controls and 
metabolically stressed constructs. Unlike traditional histological and functional tissue analyses, 
label-free OMI has the advantage of being non-invasive. 
 To study structural composition at a molecular level, second harmonic generation (SHG) 
is a useful tool. SHG is a multiphoton microscopy technique collecting light from non-linear 
scattering processes, differing slightly from multiphoton fluorescence. SHG depends on the 
interaction of multiphoton excitation with highly polarizable, non-centrosymmetric 
structures166,170. Myosin in skeletal muscle sarcomeres and collagen in ECM are two of the few 
biomolecular structures capable of generating a SHG signal166,168,170,177. Myosin is a filamentous 
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protein with a coiled rod region and a cross-head region responsible for interaction with actin 
filaments169. The SHG signal arises from the coiled rod region, specifically, due to the non-
centrosymmetric structure of this domain. Several researchers have used myosin SHG to examine 
native skeletal muscle, extracting measures of sarcomeric spacing correlated to contractile 
function169,178-180. In one such study, muscle biopsies from healthy patients and those with Pompe 
disease were analyzed by myosin SHG178. Pompe disease is characterized by enlarged, glycogen-
filled lysosomes and autophagic debris in muscle fibers, resulting in widespread sarcomere 
disruption. After acquiring myosin SHG images, subsequent processing of sarcomeric spacing and 
alignment data was used to generate a score indicating the condition of the muscle. These values 
were then used to distinguish between healthy and diseased patients, providing a potential tool 
for assessing muscle health. Similarly, collagen SHG has been used to image the triple helical 
fibrillar collagen structure in a range of tissues177. The SHG signal is sensitive to the fiber structural 
organization and especially to changes due to disorders such as fibrosis and connective tissue 
disorders. In engineered tissues specifically, it has been utilized to assess structural organization 
of engineered heart valves, detecting the difference in collagen deposition by cells cultured under 
normal and supraphysiological conditions181,182.  
While these studies demonstrate the efficacy of the OMI techniques proposed, to date 
most have collected data from fixed samples, not living tissues. Furthermore, the majority  of 
published data examines native tissues, not engineered tissues166,167,169,178,179. Thus, there exists 
a lack of knowledge about label-free, nonlinear OMI in engineered tissue. In this study, I combine 
these two complementary OMI methods to obtain redox ratio values indicative of metabolic 
activity and SHG of structural organization as measures of the overall integrity of our tissue-
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engineered SMUs. Thus, our goal was to use known protocols to alter the structural integrity and 
metabolic activity within our engineered tissues and to determine if these perturbations could 
be monitored using OMI. Additionally, we sought to demonstrate applicability of the reliable 
method previously demonstrated in our work167 for non-destructive and quantitative evaluation 
and characterization to engineered skeletal muscle tissue. Such optical measures could serve as 
reliable release criteria for cell-based tissue-engineered constructs prior to human implantation, 




All animal care procedures followed The Guide for Care and Use of Laboratory Animals137, 
according to a protocol approved by the University Committee for the Use and Care of Animals. 
As described in Chapter II, SMUs were engineered from female Fischer 344 rats.  
Muscle Dissection and Cell Isolation 
To yield a single cell suspension, muscles were processed using the protocol described in 
Chapters II and III. Both soleus muscles were removed, minced using a razor blade, and digested 
in a dissociation solution containing dispase and type IV collagenase. The resulting suspension 
was then filtered, centrifuged, and the cells were resuspended in growth medium for seeding. 
SMU Formation  
  SMUs were engineered as described in Figure 9 and in previous work from our 
laboratory72,140. In this study, 3 variations of this established SMU fabrication protocol were used. 
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The first group (Control) contained SMUs fed every 48 hours as per our published protocol72, 
prior to studying the addition of dexamethasone. The second group (Metabolic Stress) had its 
metabolic activity altered through feeding every 72 hours. The third group (Steroid Supplement) 
of SMUs were fed every 48 hours and supplemented with dexamethasone to generate improved 
myogenesis and structural advancement140. Isolated cells were divided evenly between 
experimental groups, allowing all three to begin with cells that were essentially equivalent. To 
accommodate the constraints of the microscope, custom 60mm polystyrene dishes were used 
for SMU fabrication. After curing PDMS onto each plate, the substrate was removed and punched 
with a 46 mm punch (McMaster-Carr, Elmhurst, IL, cat no. 3418A46). This central portion of this 
layer of PDMS was then replaced in the polystyrene dish, coated with laminin at 1mg/cm2, and 
used for seeding. After initial plating, cells were left unaltered for four days to allow attachment 
and were subsequently fed muscle growth medium (MGM) as per the feeding schedule for each 
experimental group until becoming fully confluent on Day 7 with a network of elongating 
myotubes. At this point, 5 mm tissue-engineered bone-tendon anchors were pinned onto the cell 
monolayers at a spacing of 2.5 cm, and the media was switched to muscle differentiation medium 
(MDM). After a week on MDM, the monolayers delaminated from the plates on Day 14, rolling 
into cylindrical muscle constructs, held at length by the engineered bone anchors.  
Evaluation of SMU Contractile Properties 
To evaluate force production29,72,140, one end of the SMU was attached to a force 
transducer with a 0-5 mN range and a 0.4 μN resolution, and platinum wire electrodes were 
placed along either side of the SMU for field stimulation. Passive tension was measured prior to 
stimulation. Peak tetanic force was determined after subtracting the passive tension baseline in 
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response to a 1 s train of 5 ms pulses at 90 mA and 60 Hz, and data files for force traces were 
recorded and analyzed using LabVIEW 2013. 
Non-linear Optical Molecular Imaging 
OMI was performed on a Leica TCS SP5 microscope equipped with an ultrafast-pulsed 
Ti:sapphire laser (Spectra-Physics, Mountain View, CA, cat. no. “Mai-Tai”). The excitation laser 
source and emitted light were coupled through an inverted microscope with a 25X water 
immersion objective lens (0.95 NA, 2.5 mm working distance) to image developing muscle 
monolayers and 3D SMUs. Prior to measurement on the inverted microscope, the PDMS 
substrate and monolayers were flipped over onto custom measurement dishes with the 
polystyrene bottom removed and replaced with a coverslip. All images were collected in a 
controlled environment at 37 °C with 5% CO2 to mimic normal tissue culture conditions. Before 
each measurement, the excitation power at the specimen surface plane at both excitation 
wavelengths with a 10X objective was calibrated at 20 mW for cell monolayers and 30 mW for 
3D SMUs to limit photobleaching and nonreversible changes in the sample166,183. All imaging was 
thus performed at incident power levels below 30 mW, since such excitation has proven non-
damaging after thousands of scans183. Furthermore, the ability of the engineered tissue to 
assume 3D form and produce contractile force comparable to historical values72,140 suggests that 
OMI analysis did not adversely affect tissue health or function. 
 These monolayers were analyzed on Day 11 of the fabrication protocol. Because this 
procedure is sterile and non-invasive, the same monolayers were evaluated again on Day 16 
following 3D formation and contractile properties measurement. 3D SMUs were transferred onto 
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similar measurement dishes with a coverslip bottom and the addition of stainless steel pins to 
constrain the engineered tissue.  
For imaging of NADH and FAD molecules, two-photon excitation at 715 nm and 900 nm 
was used, respectively. Backscattered fluorescence for NADH and FAD were filtered through a 
band pass (440-490 nm for NADH and 500-550 nm for FAD) prior to collection with non-
descanned photomultiplier tubes (PMT) to increase collection efficiency. High-resolution images 
(1024 x 1024 pixels) were collected at a 200 Hz line-scanning rate, with a line average of eight to 
reduce noise. This line average value indicates each line of pixels is scanned eight times, with the 
resulting intensities combined and displayed as an average. The PMT gain was maintained at its 
maximum to keep measurements consistent between images and samples.  
For second harmonic generation imaging, 860 nm excitation was used to generate a 
myosin SHG signal169,170. To isolate this SHG signal, a 425-435 nm filter was placed in front of the 
PMT. For the collagen SHG signal, 900 nm excitation and a 395-405 nm filter was used169,170. Since 
SHG is a scattering process, its intensity is highly dependent on direction. In relatively thicker 
samples, such as the 3D SMU, back-scattered myosin and collagen SHG signals dominate, and a 
PMT on the same side of the sample as the excitation was employed. For the thinner monolayers, 
forward-scattered SHG signals were captured with a PMT on the opposite side of the sample 
form the excitation. As with metabolic activity imaging, high-resolution images (1024 x 1024 
pixels) were collected at a 200 Hz line-scanning rate with a line average of eight to reduce noise. 
The PMT gain was set at maximum for every measurement. 
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From each sample, 6 images were captured by sequentially scanning for myosin SHG, 
collagen SHG, FAD, and NADH. These sample sizes were chosen based on previous work using 
OMI to detect differences in control and stressed engineered oral mucosa167.  
 
Redox Ratio Calculation 
For analysis of metabolic activity, the raw fluorescence images of NADH and FAD were 
inputs into ImageJ software (Figure 20). The collagen SHG signal was also incorporated into this 
analysis. These three images were then processed with a 3 x 3 median filter to increase image 
contrast. A threshold value, set as the average fluorescence intensity signal from the whole 
image, created a binary mask to reduce background fluorescence signals. This binary mask 
 
Figure 20. OMI processing schematic. Raw images were analyzed in ImageJ. Pre-processing 
involved noise reduction with a 3 x 3 median filter and subtraction of background fluorescence 
signals. For the metabolic indicators, NADH and FAD, the collagen SHG signal was subtracted 
from each to remove collagen regions. For the structural indicators, myosin and collagen, each 
SHG signal was subtracted from the other to remove overlapping regions. 
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filtered each raw NADH and FAD fluorescence image. In the collagen SHG image, pixels having 
intensity greater than the average SHG signals from the whole image were subsequently 
subtracted from the corresponding NADH and FAD fluorescence images. Following removal of 
background noise and collagen signals, the processed NADH and FAD images were then used to 
derive a redox ratio (RR) at each image pixel as [FAD] / ([NADH] + [FAD]). Ultimately, the average 
RR across the entire image was used to quantify local intracellular metabolic activity, providing a 
quantitative parameter with minimized background artifacts184-187.  
Structure Ratio Calculation 
Myosin and collagen SHG signals were analyzed to obtain a structure ratio metric 
indicative of engineered tissue structural composition (Figure 20). Each pair of images were first 
processed with a 3 x 3 median filter in ImageJ to increase image contrast. A binary mask, based 
on a threshold at the average image intensity, was used to reduce background. Next, pixels 
having intensity greater than the average collagen SHG signal from the whole image were 
subsequently subtracted from the corresponding myosin SHG imaging, and vice versa. After 
removing noise and overlapping SHG signals, an average structure ratio was calculated for each 
image as [Myosin] / ([Myosin] + [Collagen]). 
Immunocytochemical and Immunohistochemical Analysis 
To validate the NADH signal, MitoTracker® (Fisher, cat. no. M-7512), an exogenous 
fluorescence dye that only fluoresces within mitochondria, was used to stain developing muscle 
monolayers. A 50 nM MitoTracker® solution was added to MDM on Day 11 of SMU fabrication 
and incubated for 30 minutes. Fresh medium was then resupplied, and samples were imaged for 
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colocalized fluorescence from both MitoTracker® and NADH. Additionally, media containing a 
metabolic inhibitor, 4 mM KCN (Sigma, cat. no. 60178), or an uncoupler, 0.5 mM FCCP (Sigma, 
cat. no. C2920), were employed to vary cellular metabolism during imaging. Variations in both 
NADH and FAD signals were monitored for 10 min, and KCN or FCCP was administered 
immediately after acquiring the first image. 
To confirm the accuracy of myosin and collagen SHG signals, following force testing and 
OMI evaluation, 3D SMUs were fixed in 20°C methanol for 10 min and set aside for IHC. Samples 
were washed for 10 min in 0.1% Triton X-100 (Sigma, cat. no. T8787) in DPBS (PBST) and blocked 
with PBST containing 3% Bovine Serum Albumin (PBST-S; Sigma, cat. no. A2153) at room 
temperature. Samples were then incubated overnight at 4°C with primary antibodies diluted in 
PBST-S. Immunofluorescent staining was performed using the following primary antibodies: 
mouse anti-myosin heavy chain (1:100 dilution; DSHB, cat. no. MF20) and rabbit anti-collagen I 
(1:200 dilution; Biorbyt, San Francisco, CA, cat. no. orb312178). Following 3 PBST washes for 5 
min each, samples were incubated in a 1:500 dilution of Alexa Fluor secondary antibodies (Life 
Technologies) for 3 hours at room temperature. Following 3 washes in PBST for 15 min each, 
samples were preserved in Prolong Gold with DAPI (Life Technologies, cat. no. P36935) and cover 
slipped. Samples were then examined for colocalization of the antibody fluorescence and SHG 
signals.  
Statistical Analysis 
All values are presented as mean ± standard error. Measurements of significant 
differences between means were performed using GraphPad software. Means were compared 
using either a Student’s t-test or one-way ANOVA with Tukey post-hoc comparisons. Correlation 
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between experimentally measured OMI metrics and contractile force values was assessed based 
on the Pearson correlation coefficient, r. Differences were considered significant at p<0.05. 
 
Results 
Metabolic Activity in Muscle Monolayers and 3D SMUs 
The multiphoton fluorescence signal for NADH was validated using cells labelled with 
MitoTracker®. Colocalization of the NADH and MitoTracker® signals confirmed the presence of 
NADH in cell mitochondria as expected (Figure 21). Treatment with the metabolic inhibitor, KCN, 
and the metabolic uncoupler, FCCP, also produced the expected variations in NADH and FAD 
(Figure 21). Specifically, KCN inhibits complex IV of the electron transport chain, increasing NADH 
and decreasing FAD concentrations. Following KCN addition, the normalized NADH intensity for 
treated cells increased approximately 3-fold over the 10 minutes of observation, while the FAD 
intensity decreased by half. On the other hand, FCCP uncouples electron transport and drives the 
metabolic pathway to oxidation, decreasing NADH and increasing FAD concentrations. In living 
cells, an initial increase in FAD intensity was observed 2 minutes after FCCP treatment, before 
values returned to baseline levels. The normalized NADH intensity decreased approximately 4-
fold in response to addition of FCCP.  
  After confirming the sensitivity of the NADH and FAD signals to variations in metabolic 
activity, images from the control and metabolically stressed tissues were analyzed to obtain RR 
values. As mentioned previously, the redox ratio, defined as [FAD]/([NADH] + [FAD])167, is a 
quantitative metric to compare relative metabolic rates of measured samples. Because a lower 
RR indicates a higher cellular metabolic rate, with relatively lower FAD fluorescence and higher 
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NADH fluorescence, values in this study are presented as the inverse RR. As a result, higher 
inverse RR values indicate greater metabolic activity.  
            
This inverse RR metric was used to assess cell metabolism in engineered skeletal muscle 
monolayers and in 3D SMUs. Representative raw fluorescence images from which RR metrics 
were extracted are shown in Figure 22. In monolayer form, control plates (n = 9) exhibited 
significantly greater (p = 0.02) inverse RR values (0.66 ± 0.04) than metabolically stressed cells 
(0.55 ± 0.03). Similarly, after formation of a 3D SMU, images of control tissues (n = 9) yielded 
average inverse RR values of 0.46 ± 0.02, which were significantly greater than 0.40 ± 0.02 in the 
 
Figure 21. OMI signal validation. (A) Colocalization of the NADH and MitoTracker® signals 
confirmed the source of the OMI NADH signal. Sections of 3D SMUs visualized using both IHC and 
OMI for (B) myosin SHG and (C) collagen SHG validated the source of the myosin and collagen 
SHG signals. Treatment with (D) the metabolic inhibitor, KCN, and (E) the metabolic uncoupler, 
FCCP, produced the expected variations in NADH and FAD. Following KCN addition (indicated by 
the red arrow), OMI observed increasing NADH and decreasing FAD concentrations. FCCP led to 
decreasing NADH concentrations and FAD concentrations that increased initially before returning 
to baseline levels. 
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metabolic stress group (p = 0.04). When comparing all values for metabolic activity by imaging 
time point, a significant decrease (p < 0.01) in inverse RR value was observed in 3D SMUs (0.46 ± 




Figure 22. Endogenous NADH and FAD fluorescence as indicators of metabolic activity. NADH and FAD are 
mitochondrial coenzymes that function in cell metabolism and oxygen consumption. NADH fluorescence was 
excited at 715 nm, and emitted light was filtered in a band from 400-475 nm. FAD fluorescence was excited at 900 
nm and was captured from 500-600 nm. Representative images of these signals are shown above for engineered 
tissues (A) in monolayer form and (C) in SMU form. For each engineered tissue, n=6 images were recorded. 
Following processing of captured images as described in Figure 20, a redox ratio metric was calculated as [FAD] / 
([NADH] + [FAD]). The calculated redox ratios are summarized graphically for monolayers in (B) and for 3D SMUs 
in (D). For engineered tissues in monolayer form, metabolic stress significantly increased (p = 0.02) the redox ratio 
to 0.45 ± 0.06, as compared to the average control redox ratio of 0.34 ± 0.02. After formation of a 3D SMU, redox 
ratios in both groups increased. Again, the average redox ratio in the metabolic stress group, 0.60 ± 0.04, was 
significantly greater (p = 0.04) than that of the control group, 0.54 ± 0.02. Differences are considered significant at 
p < 0.05. Values are presented as Mean ± Standard Error, and * indicates significant difference from control. 
89 
 
Structural Organization in Monolayers and 3D SMUs 
 As with the metabolic fluorescence signals, engineered tissues were simultaneously 
analyzed with both OMI and with IHC to validate the source of the myosin and collagen SHG 
signals. Following cryosectioning and staining with fluorescent antibodies for either myosin heavy 
chain or collagen type I, samples of 3D SMUs were imaged and examined for colocalization of the 
SHG signal with the antibody fluorescence (Figure 21).  
Furthermore, the myosin SHG signal in fixed samples of native and engineered skeletal 
muscle was examined for the presence of advanced sarcomeric organization. Without any 
exogenous labelling reagent, both native and engineered myofibers exhibited a dense network 
of parallel sarcomeres (Figures 23A & B). The average sarcomere length measured in these 
images (2.5 ± 0.4 μm in native, 2.6 ± 0.2 μm) matched the historical range from 2.4 to 2.9 μm.  
Additionally, in living engineered SMUs, sarcomeric organization was evident during collection of 
the myosin SHG signal (Figure 23C).   
 
 After confirming the accuracy of the myosin and collagen SHG signals, images from the 
control and steroid supplemented tissues were analyzed to obtain structure ratio (SR) values 
 
Figure 23. Myosin SHG in native and engineered skeletal muscle. Light scattered from myosin filaments was 
captured from fixed samples of (A) a native muscle section and (B) an engineered SMU. From such images (n = 
12), the average sarcomere length measured in native muscle was 2.5 ± 0.4 μm. This value was statistically 
equivalent (p = 0.005) to the average sarcomere length of 2.6 ± 0.2 μm measured in engineered skeletal muscle. 
The average sarcomere length in rat skeletal muscle varies from 2.4 to 2.9 μm, and the values measured in 
engineered muscle fall within this range. (C) In living engineering SMUs, sarcomeric structure was evident from the 
myosin SHG signal. This OMI technique has not been demonstrated previously in living engineered tissue. 
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modelled after the RR metric in the previous section. The structure ratio was defined as [Myosin] 
/ ([Myosin] + [Collagen]) to create a quantitative metric for comparing the relative structural 
composition of these two key proteins. Representative raw images of the myosin and collagen 
SHG signals are shown in Figure 24. From these images, SR values were calculated and used to 
compare experimental groups.  
 
 
Figure 24. Myosin and collagen SHG as indicators of structural organization. SHG signals from myosin and 
collagen were collected in response to excitation at 860 nm and 920 nm, respectively. Due to the nature of SHG, 
scattered light was captured at half the excitation wavelength, 425-435 nm for myosin and 455-465 nm for collagen. 
Representative images of the two are pictured in (A) for engineered tissues in monolayer form and in (C) as 3D 
SMUs. n = 6 images were recorded for each sample. Following image processing summarized in Figure 20, a 
structure ratio was calculated as the myosin density relative to the combined myosin and collagen density. These 
ratios for monolayers are summarized in (B) and for 3D SMUs in (D). In monolayer form, steroid supplementation 
significantly increased (p < 0.01) the structure ratio to 0.85 ± 0.03, as compared to control at 0.57 ± 0.04. Similarly, 
the average ratio with steroid supplement, 0.79 ± 0.03, was significantly greater (p < 0.01) than that of the control 
SMUs, 0.65 ± 0.02. Differences are considered significant at p < 0.05. * indicates significant difference from control. 
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Steroid supplemented monolayers (n = 9) yielded significantly greater (p < 0.01) SR values 
(0.85 ± 0.03) than control plates (0.57 ± 0.04). In 3D SMU form, steroid supplemented tissues (n 
= 9) exhibited average inverse SR values of 0.79 ± 0.02, which were significantly greater (p < 0.01) 
than the average of 0.65 ± 0.03 in controls. When comparing structural composition values by 
imaging time point, no significant difference (p = 0.70) in SR value was observed between 
monolayers (0.65 ± 0.03) and 3D SMUs (0.67 ± 0.02). 
Contractile Properties of 3D SMUs 
Overall function of engineered SMUs was assessed by measuring passive tension and 
contractile force production on Day 15, following monolayer delamination and capture in 3D 
form. As shown in Figure 25, no significant differences in passive force generation were observed 
among the three groups. Control SMUs (n = 9) exhibited average passive tensions of 2370 ± 785 
µN, slightly higher (p = 0.208) than the average tension of 1260 ± 333 µN in steroid supplemented 
SMUs, and slightly lower (p = 0.554) than the average tension of 2970 ± 591 µN in metabolically 
stressed SMUs. The peak isometric tetanic force generated in response to electrical stimulation 
was also similar in control SMUs (67 ± 22 µN) and metabolically stressed SMUs (45 ± 12 µN, p = 
0.391). SMUs in the steroid supplement group exhibited active forces of 287 ± 82 µN, significantly 
greater than control forces (p = 0.028).   
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Correlation between OMI Metrics and Functional Measures 
 To evaluate the potential of the OMI metrics for evaluation of engineered skeletal muscle 
tissue, redox ratio and structure ratio values from samples were compared to the current gold 
standard for functional evaluation, contractile force production. A weak, non-significant 
correlation (Pearson r = 0.26, p = 0.19) was observed between inverse RR and force production 
in 3D SMUs (Figure 25). On the other hand, a significant correlation (p < 0.01) was measured 
 
Figure 25. Comparison of SMU contractile properties and OMI measures. The 
ability of 3D SMUs to generate force was used to measure tissue function. (A) Passive 
force was measured as resting tension generated by the engineered tissue, and (B) 
active force was measured in response to tetanic electrical stimulation after 
subtracting resting tension. Steroid supplementation significantly increased active 
force generation, 287 ± 82 µN, as compared to control, 67 ± 22 µN (p = 0.028). When 
comparing functional and OMI measures, (C) correlation was not evident between 
metabolic activity and force, and (D) a clear correlation was present between overall 
myosin density and active force generation. Differences are considered significant at 
p < 0.05. Values are presented as Mean ± Standard Error, and * indicates significant 
difference from control.   
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between structure ratio and force production, with a Pearson correlation coefficient of 0.62. 
Furthermore, comparing OMI measures of myosin density alone to force production values 
demonstrated the strongest correlation (r = 0.93, p < 0.01). 
 
Discussion 
This work demonstrates the potential for using label-free optical molecular imaging to 
characterize and evaluate tissue-engineered skeletal muscle constructs. In both monolayers and 
3D SMUs, the novel OMI measures successfully evaluated metabolic activity and structural 
organization. Previous work with tissue-engineered SMUs has determined that generation of 
contractile force greater than 100 μN serves as suitable threshold with which to judge constructs 
viable for implantation29,72,127,145. As a result, the optical approaches described in this work were 
first validated in tissue-engineered skeletal muscle and subsequently compared to functional 
evaluation of peak tetanic force production.  
 The potential of label-free OMI for evaluation of tissue viability has been demonstrated 
in biopsies from native skeletal muscle169,178,180 and in engineered oral mucosa167, and the ability 
to use such methods for a diverse range of engineered tissues holds great promise for advancing 
the field as a whole. In this study, cell metabolic activity, primarily contained within fluorescence 
signals from metabolic coenzymes NADH and FAD, was obtained by optically imaging thin cellular 
layers. Because OMI was performed in a non-invasive manner without the need for preservation 
or exogenous labelling reagents, metabolic activities were evaluated at multiple time points 
without adversely affecting the tissue engineering process. Using the redox ratio metric extracted 
from these signals, we successfully differentiated control and metabolically stressed engineered 
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tissues. A non-significant correlation relating increased metabolic activity to increased force 
production was observed, suggesting OMI measures of metabolism alone may not be sufficient 
to evaluate SMU suitability for implantation. Overall, decreased metabolic activity was detected 
through the RR metric in both metabolically stressed monolayers and 3D SMUs. 
 Additionally, OMI captured essential information describing structural composition 
through myosin and collagen SHG signals. The myosin SHG signal, in particular, shows great 
promise for the evaluation of organized sarcomeric structure in tissue-engineered skeletal 
muscle. In this study, I captured high-resolution images of myosin SHG in fixed native and 
engineered tissues and extracted sarcomere lengths indicative of tissue structural maturity. 
Furthermore, we demonstrated novel applicability of myosin SHG by imaging sarcomeric 
structure in living engineered tissue. Utilizing the ratio of myosin to collagen SHG signals, I was 
able to quantify structural development in our engineering tissues. The efficacy of the structure 
ratio metric was then demonstrated by distinguishing between dexamethasone-supplemented 
and control samples. Using OMI we were able to show that the addition of dexamethasone 
increased the relative myosin content, quantified by the structure ratio metric, in both 
developing muscle monolayers and 3D SMUs relative to control tissues. Furthermore, a relation 
between the structural OMI measures and force production was evident. As would be expected 
based on skeletal muscle contractile mechanics, increased myosin density observed through OMI 
was significantly correlated to increased force production. Ultimately, this positive correlation 
suggests OMI measures of SMU structure could potentially serve as an accurate predictor of 





In this work, we demonstrated the potential of non-invasive optical techniques to provide 
manufacturing release criteria that correlate to functional measures of engineered skeletal 
muscle. The optical methods described here were previously used for quality control of tissue-
engineered oral mucosa167, and this use in an engineered skeletal muscle in this work suggests 
applicability for a variety of other tissues. Because nonlinear OMI has the ability to optically 
penetrate several hundred microns into tissues, this approach should be suitable for other 
engineered cell-based devices. Additionally, this approach could be employed to evaluate the 
integration and maturation of implanted tissues in vivo during the regeneration process, whether 
through a microendoscope and or an imaging window169,172. This work illustrates how OMI 
techniques could benefit the fabrication of tissue-engineered products by enabling non-
destructive analysis of engineered tissues in real-time. Using this approach, reliable tools for 
providing quantitative measures of engineered tissue viability can enable selection of the 
healthiest engineered tissues for implantation, thereby improving therapeutic outcomes and 








This work sought to develop methods for improving contractile force production in tissue-
engineered skeletal muscle. Although engineered skeletal muscle tissues hold great potential as 
a graft source for repairing muscle damage, a significant barrier to clinical translation is the ability 
to fabricate tissue with an adult phenotype in vitro160,161. Rapid maturation towards the adult 
phenotype does occur with implantation in vivo72, and it is hypothesized that improving the 
structure and function of engineered SMUs prior to implantation would unlock the maximum 
regenerative potential of these engineered tissues. 
The first aim of this dissertation demonstrated how microfluidic separation utilizing a 
Labyrinth device was able to purify satellite cells from the heterogeneous population of isolated 
cells. From initial optimization experiments, sorting at a flow rate of 1800 μL/min yielded the 
greatest separation of fluorescently labelled mouse cells. Rat cells isolated according to the 
established SMU fabrication protocol and sorted by the Labyrinth subsequently demonstrated 
significant enrichment of the myogenic population, increased myogenic proliferation and 
differentiation, and improved SMU function. Thus, microfluidic sorting was shown to efficiently 
separate satellite cells from fibroblasts while ultimately improving the force production in 3D 
SMUs engineered from the purified population.  
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In the second aim, several experimental doses of dexamethasone and timing of 
administration were studied to maximize the beneficial effects of this glucocorticosteroid on 
myogenic differentiation140. In developing muscle monolayers, treatment with 10 and 25nM Dex 
significantly increased myogenic proliferation, early and late differentiation, and structural 
maturation. Ultimately, addition of 10nM DEX beginning on Day 0 or Day 6 led to a five-fold 
increase in force production in 3D SMUs. From these results, it was clear that dexamethasone 
supplementation could be employed to enhance structure and function of engineered skeletal 
muscle tissues.  
The third aim developed optical molecular imaging (OMI) methods to non-invasively 
evaluate engineered SMUs, potentially removing the need for invasive, non-sterile functional 
measures prior to use for repair of volumetric muscle loss. In this study, redox ratios indicative 
of tissue metabolic activity extracted from NADH and FAD fluorescence successfully distinguished 
control and metabolically-stressed SMUs. Similarly, the OMI ratio metric comparing myosin and 
collagen SHG differentiated control SMUs from those supplemented with dexamethasone. 
Among these OMI measures, myosin density correlated to SMU force production, suggesting this 
technique can predict SMU force production and could potentially replace this functional 
measure. Overall, this study demonstrated the potential of OMI for evaluating metabolism and 
structure in engineered SMUs without the need for addition of exogenous labelling reagents or 
destructive sample preparation.  
As intended in the initial experimental designs, the three studies demonstrated means 
for either increasing force production or removing evaluation methods that potentially damage 
and decrease force production in tissue-engineered skeletal muscle in vitro. The applicability of 
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these novel methods is evident from incorporation of microfluidic sorting with the Labyrinth and 
addition of 10nM dexamethasone into our current SMU fabrication protocol. With additional 
development and refinement, it is expected that the OMI techniques developed in this work will 
be incorporated as well. With consistent improvements in force production in vitro through the 
methods established in this dissertation, tissue-engineered skeletal muscle is closer to utility as 
a graft for repairing VML. This work is thus essential for advancing our tissue engineering model 
towards clinical translation. It is hoped that these and similar techniques can be applied to 
advance the tissue engineering and regenerative medicine field as a whole. 
To continue advancing our engineered skeletal muscle, several future directions will play 
an essential role. In addition to the methods for promoting advanced in vitro myogenesis 
described in this dissertation, researchers have applied mechanical stimuli seeking to further 
recreate the in vivo environment. These systems can range from aligned, cylindrical microwells 
or micropatterned substrates designed to promote alignment and fusion into myotubes71,188,189 
to dynamic bioreactors for providing cyclic strain through either fluid flow or mechanical 
stretch30,73. Maximizing in vitro advancement of engineered tissues by utilizing both these 
mechanical stimuli and the techniques developed in my research have the potential to decrease 
even further the gap between our SMUs and native skeletal muscle.  
The ultimate success of these engineered SMUs will depend on their ability to regenerate 
damaged muscle. Thus, future studies will fabricate engineered skeletal muscle characterized by 
increased myogenesis and improved in vitro force production for implantation into a model of 
volumetric muscle loss72. It is expected that in vitro phenotypic advancement will translate to 
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improved in vivo regeneration, and these implantation studies will reveal the degree to which 
this hypothesis is applicable.  
Finally, scaling up of the engineered skeletal muscle from a rat model to a large animal 
model will be essential for achieving clinical relevance. Although the need for improved 
vascularization of these larger engineered tissues will prevent a significant challenge, previous 
work in our laboratory in scaling up tissue-engineered bone and ligament constructs will provide 
a model for this future research139,190. Additionally, recent studies have demonstrated potential 
methods for promoting vascularization of engineered skeletal muscle to maintain in vitro viability 
and metabolic activity and to promote anastomosis with native vasculature in vivo following 
implantation26,154. An additional challenge to the scaling up of our engineered SMUs is the limited 
proliferative capacity of muscle satellite cells. Isolated satellite cells can only be expanded to a 
limited extent, because myogenic potential rapidly decreases after a period of two weeks in 
vitro33,80,92. Developing methods to maintain the stem cell capacity for self-renewal in satellite 
cells will be essential as we seek to expand these cells for engineering skeletal muscle tissues 
suitable for repair of large-scale VML defects. With these goals and challenges in mind, it is 
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